

10/075,635

=> d his

(FILE 'HOME' ENTERED AT 10:05:34 ON 29 APR 2004)

FILE 'STNGUIDE' ENTERED AT 10:05:44 ON 29 APR 2004

FILE 'HOME' ENTERED AT 10:06:18 ON 29 APR 2004

FILE 'REGISTRY' ENTERED AT 10:06:21 ON 29 APR 2004

L1 STRUCTURE UPLOADED
L2 QUE L1
L3 34 S L2
L4 659 S L2 SSS FUL

FILE 'CAPLUS' ENTERED AT 10:06:44 ON 29 APR 2004

L5 40 S L4
L6 ANALYZE L5 1- RN HIT : 659 TERMS

FILE 'REGISTRY' ENTERED AT 10:07:05 ON 29 APR 2004

L7 100 S 193752?/RN
L8 3 S L4 AND L7
L9 656 S L4 NOT L8


FILE 'CAPLUS' ENTERED AT 10:09:43 ON 29 APR 2004

L10 30 S L9
L11 27 S L10 AND PATENT/DT
L12 3 S L10 NOT L11
L13 3 S L12 AND PD>1999

=> d 12

L2 HAS NO ANSWERS

L1 STR




Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 APPLICATION NUMBER: 2004/142799 CAPLUS
 DOCUMENT NUMBER: 140:164138
 TITLE: Preparation of antibacterial erythromycin derivatives with improved pharmacokinetic profiles
 INVENTOR(S): Clark, Richard F.; Djuric, Stevan; Ma, Zhenkun; Phan, Ly; Rupp, Michael
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 16 pp.
 CODE: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004033970	A1	20040219	US 2003-422111	20030424
PRIORITY APPL. INFO.:			US 2002-377001P	P 20020430
OTHER SOURCE(S):		MARPAT 140:164138		

GI




AB Antibacterial erythromycin derivs. I, wherein R1 is H, Ac, Bz, TMS, triethylsilyl; R2 is -CH=CH-, -C≡C-, -C≡C-; R3 is heterocycle, tetra-azoly, furanyl, imidazolyl, iso-thiazolyl, isoxazolyl, naphthyl, 1,2,3-oxadiazolyl, oxazolyl, Ph, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, pyridyl (pyridinyl), thienyl (thiophenyl), 1,3,5-triazinyl, 1,2,3-triazolyl; X is H, F, heterocycle; with improved pharmacokinetic profiles and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compds. containing the compds., and methods for prophylaxis and treatment of bacterial infections using the compds. are disclosed. Thus, (3aS,4R,7R,9R,10R,11S,13R,15R,15aR)-10-((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy-4-ethyl-7-fluoro-3a,7,9,11,13,15-hexamethyl-11-((2E)-3-(5-(2-

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 methyl-2H-tetrazol-5-yl)thien-2-yl)prop-2-enyl)oxy]octahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazole-2,6,8,14(1H,7H,9H)-tetrone was prep. and tested as antibacterial agent. The daily therapeutically effective amt. of the compds. administered to a patient in single or divided doses range from about 0.1 to about 200 mg/kg body wt., preferably from about 0.25 to about 100 mg/kg body wt. Compds. of this invention displayed antibacterial activity superior to the control, which control demonstrated no antibacterial activity. The pharmacokinetic profiles were evaluated using cassette dosing protocols in dog at a dose of 1 mg/kg.

IT 619296-66-1P 619296-71-8P 619296-72-9P
 619296-73-0P 619296-74-1P 619296-75-2P
 619296-80-9P 619296-81-0P 623175-51-9P
 623175-52-0P 623175-53-1P 623175-54-2P
 623175-55-3P 623175-56-4P 623175-57-5P
 623175-58-6P 623175-59-7P 623175-67-7P
 623175-68-8P 623175-69-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)

RN 619296-66-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 619296-71-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 619296-72-9 CAPLUS
 CN 2H-Tetrazole-2-propanenitrile, 5-[5-[3-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-2-thienyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 619296-73-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 619296-74-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 619296-75-2 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thiazolyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 619296-80-9 CAPLUS

CN 2H-Tetrazole-2-acetic acid, 5-[5-[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 619296-81-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[[3-[5-[2-(2-propenyl)-2H-tetrazol-5-yl]-2-thienyl]-2-propenyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 623175-53-1 CAPLUS

CN 2H-Tetrazole-2-propanenitrile, 5-[5-[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-2-thienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 623175-54-2 CAPLUS

CN 2H-Tetrazole-2-acetic acid, 5-[5-[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 623175-51-9 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[[(2E)-3-(2-methyl-2H-tetrazol-5-yl)-2-propenyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 623175-52-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[[3-[5-[2-(2-propenyl)-2H-tetrazol-5-yl]-2-thienyl]-2-propenyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 623175-55-3 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[[3-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 623175-56-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[[3-[2-(2-methyl-2H-tetrazol-5-yl)-5-thiazolyl]-2-propenyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 623175-57-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-
 2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 623175-58-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(1-methyl-
 1H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 623175-68-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(1-methyl-
 1H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 623175-69-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(1H-
 tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 623175-59-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(1H-
 tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 623175-67-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[2-(2-methyl-
 2H-tetrazol-5-yl)-5-thiazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 619296-70-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of antibacterial erythromycin derivs. with improved
 pharmacokinetic profiles)
 RN 619296-70-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-
 [[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thiazolyl]-2-propynyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 412046-92-5P 619296-51-4P 619296-59-2P
 619296-60-5P 619296-62-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of antibacterial erythromycin derivs. with improved
 pharmacokinetic profiles)
 RN 412046-92-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-
 (2-propynyloxy)-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 619296-51-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 619296-59-2 CAPLUS
CN Boronic acid, [(1E)-3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 619296-60-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 619296-62-7 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(2-propenyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)


Absolute stereochemistry.



L11 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN

ABSTRACTION NUMBER: 2004:60129 CAPLUS
DOCUMENT NUMBER: 140:122755
TITLE: 9-Oxime macrolide antibacterials
INVENTOR(S): Searle, Xenia Beebe; Djuric, Stevan; Ma, Zhenkun; Yang, Fan
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 18 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004014691	A1	20040122	US 2003-420391	20030422
PRIORITY APPLN. INFO.:			US 2002-375361P	20020425
OTHER SOURCE(S):			MARPAT 140:122755	



AB Antibacterial compds. I (R1 = alkyl, (CH2)alkenyl, (CH2)alkynyl, etc.; R2 = H, alkyl, (CH2)alkenyl, (CH2)alkynyl, etc.; R3 = H, hydroxyl protecting group; one of R4 and R5 = H and the other = OH or R4 and R5 = -O; X1 = H, F) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing


the compds., and methods for prophylaxis or treatment of bacterial infections using the compds. are disclosed. Compds. displayed antibacterial activity of 0.008-128 µg/mL against Staphylococcus aureus, Streptococcus pyogenes, S. pneumoniae, Enterococcus faecalis, E. faecium, Moraxella catarrhalis, Haemophilus influenzae, and Escherichia coli.

IT 648858-19-9P 648858-20-2P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPW (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(9-Oxime macrolide antibacterials, their preparation and compns., for treatment of bacterial infections)

RN 648858-19-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methylloxime), (3aS,4R,7S,9R,10R,11R,13R,14E,15R


L11 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 ,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 648858-20-2 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methyloxime),
 (3aS,4R,7S,9R,10R,11R,13R,14E,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




IT 648858-19-9D, salts, prodrugs 648858-20-2D, salts, prodrugs
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (9-Oxime macrolide antibacterials, their preparation and compns., for treatment of bacterial infections)
 RN 648858-19-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

AB 139:381701
 Preparation of antibacterial erythromycin derivatives with improved pharmacokinetic profiles
 Clark, Richard F.; Djuric, Stevan M.; Ma, Zhenkui; Phan, Ly; Rupp, Michael J.
 Abbott Laboratories, USA
 PCT Int. Appl., 50 pp.
 CODEN: PIXX02
 Patent
 English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093288	A1	20031113	WO 2003-0512970	20030425
W: CA, JP, MX RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
US 2003207820	A1	20031106	US 2002-136715	20020430
PRIORITY APPLN. INFO.:			US 2002-136715	A 20020430
			US 2003-422384	A 20030424
OTHER SOURCE(S):	MARPAT 139:381701			
GI				



AB Antibacterial erythromycin derivs. I, wherein R1 is H, Ac, Bz, TMS, triethylsilyl; R2 is -CH=CH-, -C.tlpbond.C-; R3 is heterocycle, tetra-azolyl, furanyl, imidazolyl, iso-thiazolyl, isoxazolyl, naphthyl, 1,2,3-oxadiazolyl, oxazolyl, Ph, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, pyridyl (pyridinyl), thienyl (thiophenyl), 1,3,5-triazinyl, 1,2,3-triazolyl; X is H, F, heterocycle; with improved pharmacokinetic profiles and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds. and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis and treatment of bacterial infections using the compds. are disclosed. Thus, (3aS,4R,7R,9R,10R,11S,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-


L11 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 hexopyranosyl]oxy]-, 14-(O-methyloxime), (3aS,4R,7S,9R,10R,11R,13R,14E,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 648858-20-2 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methyloxime),
 (3aS,4R,7S,9R,10R,11R,13R,14E,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 yloxy]-4-ethyl-7-fluoro-3a,7,9,11,13,15-hexamethyl-11-(((2E)-3-(5-(2-methyl-2H-tetrazol-5-yl)thien-2-yl)prop-2-enyl)oxy)octahydro-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone was prepd. and tested as antibacterial agent. The daily therapeutically effective amt. of the compds. administered to a patient in single or divided doses range from about 0.1 to about 200 mg/kg body wt., preferably from about 0.25 to about 100 mg/kg body wt. Compds. of this invention displayed antibacterial activity superior to the control, which control demonstrated no antibacterial activity. The pharmacokinetic profiles were evaluated using cassette dosing protocols in dog at a dose of 1 mg/kg.

IT 619296-66-1P 619296-71-8P 619296-72-9P
 619296-73-OP 619296-74-1P 619296-75-2P
 619296-80-9P 619296-81-OP 623175-51-9P
 623175-52-OP 623175-53-1P 623175-54-2P
 623175-55-3P 623175-56-4P 623175-57-5P
 623175-58-6P 623175-59-7P 623175-67-7P
 623175-68-8P 623175-69-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)

RN 619296-66-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 619296-71-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 619296-72-9 CAPLUS
 CN 2H-Tetrazole-2-propanenitrile, 5-[5-[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 619296-73-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]- (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 619296-80-9 CAPLUS
 CN 2H-Tetrazole-2-acetic acid, 5-[5-[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 619296-81-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-[2-(2-propenyl)-2H-tetrazol-5-yl]-2-thienyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]- (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 619296-74-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(2-methyl-2H-tetrazol-5-yl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]- (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 619296-75-2 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thiazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]- (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 623175-51-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]- (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 623175-52-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-[2-(2-propenyl)-2H-tetrazol-5-yl]-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]- (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 623175-53-1 CAPLUS

CN 2H-Tetrazole-2-propanenitrile, 5-[5-[3-[[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-2-thienyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 623175-54-2 CAPLUS

CN 2H-Tetrazole-2-acetic acid, 5-[5-[3-[[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 623175-57-5 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 623175-58-6 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(1-methyl-1H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 623175-55-3 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[6-(2-methyl-2H-tetrazol-5-yl)-3-pyridinyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 623175-56-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[2-(2-methyl-2H-tetrazol-5-yl)-5-thiazolyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 623175-59-7 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(1H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 623175-67-7 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[2-(2-methyl-2H-tetrazol-5-yl)-5-thiazolyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 623175-68-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[[5-(1-methyl-1H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 623175-69-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[[5-(1H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 (2-propenyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 619296-51-4 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 619296-59-2 CAPLUS
 CN Boronic acid, [(1E)-3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



IT 619296-70-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)

RN 619296-70-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 412046-92-5P 619296-51-4P 619296-59-2P
 619296-60-5P 619296-62-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)


RN 412046-92-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 619296-60-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 619296-62-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN

ACCESSION NUMBER: 2003:875124 CAPLUS
 DOCUMENT NUMBER: 139:365172
 TITLE: Preparation of erythromycin 9-oxime macrolides as antibacterial agents
 INVENTOR(S): Searle, Xenia Beebe; Djuric, Stevan; Ma, Zhenkun; Yang, Fan
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090761	A1	20031106	WO 2003-US12478	20030423
W: CA, JP, MX RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.: US 2002-131851 A 20020425			OTHER SOURCE(S): MARPAT 139:365172	
GI				




AB Antibacterial erythromycin 9-oxime macrolides I, wherein X1 is H, F; R1 is alkyl, -(CH2)alkenyl, -(CH2)alkynyl, R2 is hydrogen, alkyl, -(CH2)alkenyl, -(CH2)alkynyl, R3 is hydrogen or R, in which R is a hydroxyl protecting moiety; one of R4 and R5 is hydrogen and the other is -OH; or R4 and R5 together are -O- and salts, prodrugs, and salts of prodrugs thereof, processes for making the compds., and intermediates used in the processes, compns. containing the compds., and methods for prophylaxis or treatment of bacterial infections using the compds. are disclosed. Thus, I [R1 = 3-(quinolin-3-yl)prop-2-ynyl; R2 = methyl; R3 = hydrogen; R4 and R5 taken together are -O- and X = fluoro] was prepared and tested in vitro as antibacterial agent. Compds. of this invention displayed in vitro antibacterial activity in the range of about 0.008 µg/mL to greater than about 128 µg/mL.

IT 620155-58-0P 620155-60-4P

L11 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of erythromycin oxime macrolides as antibacterial agents)
 RN 620155-58-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methyloxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 620155-60-4 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[(5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methyloxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




IT 620155-66-0P 620155-68-2P 620155-70-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of erythromycin oxime macrolides as antibacterial agents)
 RN 620155-66-0 CAPLUS

L11 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)


CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[(1,5-naphthyridin-3-yl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methyloxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 620155-68-2 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[(6-quinolalyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methyloxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 620155-70-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[(5-(2-pyridinyl)-2-thienyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methyloxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 619296-74-1 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(2-methyl-2-tetrazol-5-yl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 619296-75-2 CAPLUS


CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2-tetrazol-5-yl)-2-thiazolyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-tetrazol-5-yl]-2-thienyl]-2-propenyl]oxy]-1-1-propenyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 619296-81-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 619296-70-7 619296-82-1


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)

RN 619296-70-7 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 619296-77-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(2-methyl-2-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 619296-80-9 CAPLUS

CN 2H-Tetrazole-2-acetic acid, 5-[5-[3-[[3aS,4R,7S,9R,10R,11R,13R,15aR]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-tetrazol-5-yl]-2-thienyl]-2-propenyl]oxy]-1-1-propenyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)


L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 619296-82-1 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 412046-92-5P 619296-51-4P 619296-59-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antibacterial erythromycin derivs. with improved pharmacokinetic profiles)

RN 412046-92-5 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 619296-51-4 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propynyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 619296-59-2 CAPLUS
 CN Boronic acid, [(1E)-3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-tetraoxo-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




L11 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 619296-60-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[5-(2-methyl-2H-tetrazol-5-yl)-2-thienyl]-2-propenyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 619296-62-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

PATENT NUMBER: 2003:591015 CAPLUS
 DOCUMENT NUMBER: 139:133786
 TITLE: Preparation of erythromycin A derived amido-macrolides for use in pharmaceutical compositions for treatment of bacterial infections
 INVENTOR(S): Ashley, Gary; Shaw, Simon James; Li, Yandong
 PATENT ASSIGNEE(S): Kosan Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 120 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003061671	A1	20030731	WO 2003-051398	20030117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003199458	A1	20031023	US 2003-347512	20030117
PRIORITY APPL. INFO.:		US 2002-350153P P 20020117		
OTHER SOURCE(S):		MARPAT 139:133786		
GI				




AB Erythromycin A derived amides, such as I (R1 = alkyl, alkenyl, alkynyl, aryl, arylalkyl, biarylalkyl, etc.; R2 = H, alkyl, alkenyl, alkynyl; R3 = H, COPh, alkanoyl; R4 = H, OH; R5 = H, OH, alkoxy, alkenyloxy, alkynyloxy;

L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 R6 = H, OMe; X = (CH₂)_m; m = 0-2), were prepd. for therapeutic use as antibacterial agents. These erythromycin A derivs. are useful for treating bacterial infections resulting from bacteria selected from the group consisting of Gram pos. bacteria, Gram neg. bacteria and anaerobic bacteria, such as *Staphylococcus aureus*, *Streptococcus epidermidis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, enterococci, *Moraxella catarrhalis*, and *Haemophilus influenzae*. Infections and diseases that may be treated using the agents include community-acquired pneumonia, acute exacerbated chronic bronchitis, acute sinusitis, tonsillitis, pharyngitis, upper respiratory tract infection, lower respiratory tract infection, skin infection, soft tissue infection, meningitis, hospital-acquired infection, bone infection, joint infection and gastric motility diseases, such as gastro-esophageal reflux disease (GERD), postoperative ileus, diabetes, and gastroparesis. Thus, 15-(6-quinolinecarboxamido)erythromycin A I (R1 = 6-quinolinyl, R2 = R3 = H, R4 = R5 = OH, R6 = OMe, X = (CH₂)₂) was prepd. via a series of steps which included bio-mediated conversion of (1)-(2S',3R')-5-chloro-3-hydroxy-2-methylpentanoate N-propionylcysteamine thioester to 15-chloro-6-deoxyerythronolide B using *Streptomyces coelicolor*, conversion of the 15-chloro-macrolide to 15-azido-6-deoxyerythronolide B, a second bio-mediated conversion of the 15-azido-macrolide to 15-azidoerythromycin A using *Saccharopolyspora erythraea*, and a subsequent amidation reaction of 2'-O-acetyl-15-azidoerythromycin A with 6-quinolinecarboxylic acid. The prepd. erythromycin A derivs. were tested for anti-microbial activity against organisms such as *S. aureus* OC4172 and *H. influenzae* ATCC49766.

IT 568629-20-9P
 RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of erythromycin A derived amido-macrolides for use in pharmaceutical compns. for treatment of bacterial infections)
 RN 568629-20-9 CAPLUS
 CN Benzeneacetamide, N-[2-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-4-yl]ethyl]-3-(2-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 568629-24-3P 568629-96-9P 568631-10-7P
 568631-18-5P 568631-28-7P
 RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of erythromycin A derived amido-macrolides for use in pharmaceutical compns. for treatment of bacterial infections)
 RN 568629-24-3 CAPLUS
 CN Benzeneacetamide, N-[2-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-4-yl]ethyl]-3-(2-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 568629-96-9 CAPLUS
 CN Benzeneacetamide, N-[2-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-4-yl]ethyl]-3-(2-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 568631-10-7 CAPLUS
 CN Benzeneacetamide, N-[2-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-4-yl]ethyl]-2-(2-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 568631-18-5 CAPLUS
 CN 1,2-Benzisoxazole-3-acetamide, N-[2-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 568631-28-7 CAPLUS
 CN 2-Oxazoleacetamide, N-[2-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-7-fluorotetradecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-4-yl]ethyl]-4-methyl-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



IT 568629-08-3P


RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of erythromycin A derived amido-macrolides for use in pharmaceutical compns. for treatment of bacterial infections)

RN 568629-08-3 CAPLUS


CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-(2-azidoethyl)-10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



AB The present invention includes erythromycin ketolides I wherein: X is hydrogen or halide; R is hydrogen or a substituted or unsubstituted moiety wherein the moiety is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl; R1 is hydrogen or a substituted or unsubstituted moiety wherein the moiety is selected from the group consisting of methyl, alkyl, alkenyl, alkynyl, aryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl; R2 is hydrogen, acyl, or a hydroxy protecting group; R3 is hydrogen, hydroxyl, or -ORa wherein Ra is a substituted or unsubstituted moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, heterocycloalkyl, and the pharmaceutically acceptable salts, esters and pro-drug forms thereof. These compds. possess anti-infective activity and are useful for the treatment of bacterial and protozoal infections. Thus, I (X = F, R = 1H-imidazo[4,5-b]pyridin-1-ylbutyl, R1 = Pe, R2 = F, R3 = OMe) was prepared and tested in vitro as antibacterial agent against *S. pneumoniae* (MIC ≤ 0.015).

IT 300841-16-1P 301320-09-2P 413592-00-4P
413592-04-8P 413592-07-1P 413592-12-8P
413592-15-1P 413592-17-3P 413592-22-8P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of erythromycin ketolides as antibacterial agents)

RN 300841-16-1 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-1-[[4-(1H-imidazo[4,5-b]pyridin-1-yl)butyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN

ACCESSION NUMBER:

2003:524045 CAPLUS

DOCUMENT NUMBER:

139:69471

TITLE:

Preparation of erythromycin ketolides as antibacterial agents

INVENTOR(S):

Hlasta, Dennis; Henninger, Todd C.; Grant, Eugene B.;

Khosla, Chaitin; Chu, Daniel T. W.; Ashley, Gary

PATENT ASSIGNEE(S):

Ortho-McNeil Pharmaceutical, Inc., USA

SOURCE:

U.S., 43 pp., Cont.-in-part of U.S. Ser. No. 550,045.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6590093	B1	20030708	US 2000-691540	20001018
US 6399582	B1	20020604	US 2000-548568	20000413
US 6458771	B1	20021001	US 2000-548584	20000413
US 6395710	B1	20020528	US 2000-550045	20000414
US 6451768	B1	20020917	US 2000-551162	20000414
WO 2002032918	A2	20020425	WO 2001-0532119	20011012
WO 2002032918	A3	20030103		
W: AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GN, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CK, GA, GN, GQ, GW, HL, HR, NE, SN, TD, TG				
AU 2002013214	A5	20020429	AU 2002-13214	20011012
EP 1345953	A2	20030924	EP 2001-981580	20011012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2001009444	A	20030218	ZA 2001-9444	20011115
US 2002156028	A1	20021024	US 2002-124988	20020417
PRIORITY APPL. INFO.:				
			US 1999-129729P	P 19990416
			US 1999-131383P	P 19990428
			US 1999-140175P	P 19990618
			US 1999-172154P	P 19991217
			US 1999-172159P	P 19991217
			US 2000-548568	A2 20000413
			US 2000-548584	A2 20000413
			US 2000-550045	A2 20000414
			US 2000-551162	A2 20000414
			US 1999-173804P	P 19991230
			US 1999-173805P	P 19991230
			US 2000-691540	A 20001018
			WO 2001-0532119	W 20011012

OTHER SOURCE(S):

MARPAT 139:69471

GI


L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 301320-09-2 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 413592-00-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(6-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 413592-04-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-[[3-(6-methoxy-3-quinolinyl)-2-propenyl]oxy]-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 413592-07-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(6-methoxy-3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 413592-17-3 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[[3-(6-chloro-3-quinolinyl)-2-propenyl]oxy]-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 413592-22-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-pyridinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 413592-12-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(7-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 413592-15-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluoro-11-[[3-(6-fluoro-3-quinolinyl)-2-propenyl]oxy]octahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 301320-11-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of erythromycin ketolides as antibacterial agents)
 RN 301320-11-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-(2-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyl)oxy]-4-propyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/075,635

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 ACCESSION NUMBER: 2003:472523 CAPLUS
 DOCUMENT NUMBER: 139:53251
 TITLE: Preparation of 6-O-acyl ketolide derivatives of erythromycin useful as antibacterials
 INVENTOR(S): Henninger, Todd C.; Macielag, Mark J.; Tennakoon, Manomi A.; Xu, Xiaodong
 PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 199 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003050132	A1	20030619	WO 2002-US37433	20021121
W:	AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DC, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UU, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.			

US 2003220272 A1 20031127
 PRIORITY APPLN. INFO.: US 2001-339566P P 20011205
 US 2002-392513P P 20020628
 OTHER SOURCE(S): MARPAT 139:53251
 GI



AB 6-O-Acyl ketolide antibacterials of formula I: wherein R1 is H, halogen, OH; Z is NH(CH2)n, (CH2)n, O-(CH2)n, NH-alkenyl, O-alkenyl, NH-alkynyl,

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

545416-05-5P 545416-06-6P 545416-07-7P
 545416-08-8P 545416-09-9P 545416-10-2P
 545416-11-3P 545416-12-5P 545416-14-6P
 545416-15-7P 545416-16-8P 545416-17-9P
 545416-18-0P 545416-19-1P 545416-20-4P
 545416-21-5P 545416-23-7P 545416-24-8P
 545416-25-9P 545416-26-0P 545416-27-1P
 545416-28-2P 545416-29-3P 545416-31-7P
 545416-32-8P 545416-33-9P 545416-34-0P
 545416-35-1P 545416-36-2P 545416-37-3P
 545416-38-4P 545416-39-5P 545416-41-9P
 545416-42-0P 545416-43-1P 545416-44-2P
 545416-45-3P 545416-46-4P 545416-47-5P
 545416-49-7P 545416-50-0P 545416-51-1P
 545416-52-2P 545416-53-3P 545416-54-4P
 545416-55-5P 545416-57-7P 545416-58-8P
 545416-59-9P 545416-60-2P 545416-61-3P
 545416-62-4P 545416-63-5P 545416-64-6P
 545416-66-8P 545416-67-9P 545416-68-0P
 545416-69-1P 545416-70-4P 545416-71-5P
 545416-72-6P 545416-73-7P 545416-74-8P
 545416-76-0P 545416-77-1P 545416-78-2P
 545416-79-3P 545416-80-6P 545416-81-7P
 545416-82-8P 545416-83-9P 545416-84-0P
 545416-85-1P 545416-86-2P 545416-88-4P
 545416-89-5P 545416-90-8P 545416-91-9P
 545416-92-0P 545416-93-1P 545416-94-2P
 545416-95-3P 545416-96-4P 545416-98-6P
 545416-99-7P 545417-00-3P 545417-01-4P
 545417-02-5P 545417-03-6P 545417-04-7P
 545417-05-8P 545417-07-0P 545417-08-1P
 545417-09-2P 545417-10-5P 545417-11-6P
 545417-12-7P 545417-13-8P 545417-14-9P
 545417-15-0P 545417-16-1P 545417-18-3P
 545417-19-4P 545417-20-7P 545417-21-8P
 545417-22-9P 545417-23-0P 545417-24-1P
 545417-25-2P 545417-27-4P 545417-28-5P
 545417-29-6P 545417-30-9P 545417-31-0P
 545417-32-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of acyl ketolide derivs. of erythromycin useful as antibacterials)

RN 545414-71-9 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-{4-(2-pyrimidinyl)phenyl}-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 O-alkenyl; n is 0-5; R2 is H, aryl, heteroaryl; R3 is H, alkyl, alkenyl, alkynyl, heteroaryl, heterocycloalkyl, arylalkenyl, arylalkynyl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, cycloalkyl, cycloalkenyl, alkoxyalkyl, alkylthioalkyl; R4 is H, hydroxy protecting group; W is substituted pyrrole, alkoxy, oxime, amine, heterocycle; X and X1 are together with the carbon atom to which they are attached form CO, CHOH, C1NA5, C1NOR5; Y and Y1 together with the carbon atom to which they are attached form CO, CHOH, C1NA5, C1NOR5; R5 is independently H, alkyl, alkenyl, alkynyl; are as described herein and in which the substituents have the meaning indicated in the description. These compds. are useful as antibacterial agents. Thus, I (R1 = R4 = H, ZR2 = H, R3 = Et, XX1 = YY1 = O; W is 1-pyrrole) was prepd. and tested in vitro as antibacterial agent (MIC = 0.06 to > 16 µg/mL). Compds. of the present invention were tested against a variety of Gram pos. and Gram neg. pathogenic bacteria resulting in a range of activities depending on the organism tested.


IT 545414-71-9P 545414-73-1P 545414-74-2P
 545414-75-3P 545414-76-4P 545414-77-5P
 545414-78-6P 545414-80-0P 545414-81-1P
 545414-82-2P 545414-83-3P 545414-84-4P
 545414-85-5P 545414-86-6P 545414-87-7P
 545414-88-8P 545414-90-2P 545414-91-3P
 545414-92-4P 545414-93-5P 545414-94-6P
 545414-95-7P 545414-96-8P 545414-97-9P
 545414-98-0P 545414-99-1P 545415-01-8P
 545415-02-9P 545415-03-0P 545415-04-1P
 545415-05-2P 545415-06-3P 545415-07-4P
 545415-08-5P 545415-10-9P 545415-11-0P
 545415-12-1P 545415-13-2P 545415-14-3P
 545415-15-4P 545415-16-5P 545415-17-6P
 545415-18-7P 545415-19-8P 545415-21-2P
 545415-22-3P 545415-23-4P 545415-24-5P
 545415-25-6P 545415-26-7P 545415-27-8P
 545415-28-9P 545415-29-0P 545415-30-3P
 545415-32-5P 545415-33-6P 545415-34-7P
 545415-35-8P 545415-36-9P 545415-37-0P
 545415-38-1P 545415-39-2P 545415-41-6P
 545415-42-7P 545415-43-8P 545415-44-9P
 545415-45-0P 545415-46-1P 545415-48-3P
 545415-49-4P 545415-50-7P 545415-51-8P
 545415-52-9P 545415-53-0P 545415-54-1P
 545415-55-2P 545415-56-3P 545415-57-4P
 545415-59-5P 545415-59-6P 545415-60-9P
 545415-61-0P 545415-63-2P 545415-64-3P
 545415-65-4P 545415-66-5P 545415-67-6P
 545415-68-7P 545415-69-8P 545415-70-1P
 545415-71-2P 545415-73-4P 545415-74-5P
 545415-75-6P 545415-76-7P 545415-77-8P
 545415-78-9P 545415-79-0P 545415-80-3P
 545415-82-5P 545415-83-6P 545415-84-7P
 545415-85-8P 545415-86-9P 545415-87-0P
 545415-88-1P 545415-89-2P 545415-90-5P
 545415-92-7P 545415-93-8P 545415-94-9P
 545415-95-0P 545415-96-1P 545415-97-2P
 545415-98-3P 545415-99-4P 545416-01-1P
 545416-02-2P 545416-03-3P 545416-04-4P

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

PAGE 1-A



PAGE 2-A




RN 545414-73-1 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545414-74-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 2-phenylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545414-75-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-phenyl-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545414-76-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-phenylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 545414-77-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 4-phenylbutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545414-78-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-phenyl-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

RN 545414-80-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 545414-81-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(5-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 545414-82-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[3-(2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.




RN 545414-83-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(2-pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 545414-84-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(3-pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A





PAGE 2-A





RN 545414-85-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(4-pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.





RN 545414-86-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(pyrazinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545414-87-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 545414-88-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.





RN 545414-90-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




RN 545414-91-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




RN 545414-92-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




RN 545414-93-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




RN 545414-94-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545414-95-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545414-96-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 545414-97-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.
 Double bond geometry as shown.



RN 545414-98-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A



RN 545414-99-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[3-fluoro-4-{1H-1,2,4-triazol-1-yl}phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A



RN 545415-01-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[6-{1H-pyrazol-1-yl}-3-pyridinyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A



RN 545415-02-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(1-phenyl-1H-pyrazol-4-yl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



RN 545415-03-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545415-04-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(1-pyrazinyl-1H-imidazol-4-yl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 545415-05-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-(2-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-06-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545415-08-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-(5-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-10-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-(6-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-(3-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-07-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-(4-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 545415-11-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (ZE)-3-(7-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

RN 545415-12-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(8-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545415-13-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(2-quinoxaliny)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545415-14-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(6-quinoxaliny)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545415-15-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(4-isoquinoliny)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-16-5 CAPLUS
 CN Carbonic acid, (2E)-3-(6-bromo-3-pyridinyl)-2-propenyl (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-17-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(2-oxazoly)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A

RN 545415-18-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(5-oxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

PAGE 1-A





PAGE 2-A

RN 545415-19-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(2-thiazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A

RN 545415-21-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(2-thienyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A


RN 545415-22-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(3-isoxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 545415-23-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 545415-24-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(1,3,4-oxadiazol-3-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 545415-25-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 545415-26-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[1-methyl-1H-benzimidazol-2-yl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 545415-27-8 CAPLUS
 CN Carbonic acid, (2E)-3-(5-bromo-2-pyrimidinyl)-2-propenyl
 (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-
 3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-
 oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-28-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-
 fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-
 [[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-
 oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(5-fluoro-2-pyrimidinyl)-2-
 propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545415-30-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-
 fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-
 [[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-
 oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(4-methyl-2-pyrimidinyl)-2-
 propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545415-32-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-
 fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-
 [[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-
 oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(4-methoxy-2-pyrimidinyl)-2-
 propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

propenyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-29-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-
 fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-
 [[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-
 oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(5-ethyl-2-pyrimidinyl)-2-
 propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-33-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-
 fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-
 [[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-
 oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(6-methyl-3-pyridazinyl)-2-
 propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-34-7 CAPLUS

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-43-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[5-(2-pyrimidinyl)-3-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-44-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(5-pyrazinyl-3-thienyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-48-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(2-pyrimidinyl)oxy]phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-45-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-(2-phenyl-5-pyrimidinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545415-46-1 CAPLUS
 CN Carbonic acid, (2E)-3-[2,2'-bithiophen]-5-yl-2-propenyl (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A




RN 545415-49-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 545415-50-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl [(3E)-4-[4-(2-pyrimidinyl)phenyl]-3-butenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545415-51-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl [4-(2-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 545415-53-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl [4-(2-pyrimidinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 545415-54-1 CAPLUS




RN 545415-52-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl [4-(3-pyridazinyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-pyrimidinyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 545415-55-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(4-pyrimidinyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-56-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(5-pyrimidinyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 545415-57-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-pyridinyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-59-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(3-pyridinyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 545415-61-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(3-pyridazinyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 545415-63-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1H-pyrazol-1-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 545415-59-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(4-pyridinyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-60-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(pyrazinyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



RN 545415-64-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-65-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-66-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-67-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1H-imidazol-1-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-70-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-71-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(2-quinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-68-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-69-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-73-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(3-quinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-74-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(4-quinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-75-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(5-quinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-76-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(6-quinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-79-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(2-quinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-80-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(3-quinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-77-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(7-quinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-78-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(8-quinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-82-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(4-isoquinolinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-83-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-oxazolyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-84-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(5-oxazolyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-85-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-thiazolyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-88-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-89-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-86-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-thienyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-87-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(3-isoxazolyl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-90-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-92-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[1-methyl-1H-benzimidazol-2-yl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-93-8 CAPLUS
 CN Carbonic acid, 3-(5-bromo-2-pyrimidinyl)-2-propynyl
 (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-94-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(5-fluoro-2-pyrimidinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-95-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(5-ethyl-2-pyrimidinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-96-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(4-methyl-2-pyrimidinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-97-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(4-methoxy-2-pyrimidinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545415-98-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(6-methyl-3-pyridazinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545415-99-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(6-methoxy-3-pyridazinyl)-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-01-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-02-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(2-pyridinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-03-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(3-pyridinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-06-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(3-pyrazinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-07-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-pyridinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-04-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(4-pyridinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-05-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(2-pyrimidinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-08-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(3-pyridinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-09-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(4-pyridinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-10-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-pyrimidinyl)-2-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-11-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(2-pyridinyl)-3-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-15-7 CAPLUS
 CN Carbonic acid, 3-[2,2'-bithiophen]-5-yl-2-propynyl (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-16-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-pyrimidinyl)oxy]phenyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-13-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(3-pyridinyl)-3-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-14-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(2-phenyl-5-pyrimidinyl)-3-thienyl]-2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-17-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 4-[4-(2-pyrimidinyl)phenyl]-3-butynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-18-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 5-[4-(2-pyrimidinyl)phenyl]-4-pentynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-19-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-pyrimidinyl)phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-20-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-pyrazinyl)phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-24-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1H-pyrazol-1-yl)phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-25-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1H-1,2,4-triazol-1-yl)phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-21-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(3-pyridazinyl)phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-23-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-pyridinyl)phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-26-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1H-1,2,3-triazol-1-yl)phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-27-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-28-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(2-quinolinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-29-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(3-quinolinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-33-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(6-quinolinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-34-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(7-quinolinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-31-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(4-quinolinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-32-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(5-quinolinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-35-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(8-quinolinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-36-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(2-quinolinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-37-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-(6-quinoxalinyloxy)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-38-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[4-(2-oxazolyl)phenyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-42-0 CAPLUS
 CN Carbonic acid, 3-(1H-benzimidazol-1-yl)propyl (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-43-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-39-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(2-pyridinyl)-2-thienyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545416-41-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 3-[5-(2-pyrimidinyl)-2-thienyl]propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-44-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-45-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(5-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-46-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[3-(2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-47-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-51-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(3-pyridazinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-52-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-49-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(3-pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-50-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(4-pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-53-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-54-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1H-1,2,4-triazol-4-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545416-55-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1H-1,2,3-triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-57-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545416-58-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-59-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545416-60-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-61-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545416-62-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-63-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[3-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545416-64-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(1-phenyl-1H-pyrazol-4-yl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545416-66-8 CAPLUS

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Double bond geometry as shown.



RN 545416-69-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(3-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545416-70-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(4-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(1-(2-pyrimidinyl)-1H-imidazol-4-yl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-67-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(1-pyrazinyl-1H-imidazol-4-yl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-68-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(2-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-71-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(5-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-72-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(6-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-73-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(7-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-74-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(8-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-78-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(4-isoquinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-79-3 CAPLUS
 CN Carbonic acid, (2Z)-3-(6-bromo-3-pyridinyl)-2-fluoro-2-propenyl (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-76-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(2-quinoxaliny)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-77-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(6-quinoxaliny)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-80-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(4-(2-oxazolyl)phenyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-81-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(4-(5-oxazolyl)phenyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-82-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-thiazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-83-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-thienyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-84-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(3-isoxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-85-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-86-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-88-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-89-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(1-methyl-1H-indol-2-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-90-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-91-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-92-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-93-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(6-methoxy-3-pyridazinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-94-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[5-(2-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-95-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[5-(3-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-96-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[5-(4-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545416-98-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545416-99-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[5-(pyrazinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545417-00-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-01-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545417-04-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-05-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[5-(2-pyridinyl)-3-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545417-02-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(4-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-03-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545417-07-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[5-(2-pyrimidinyl)-3-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-08-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[5-(2-pyrazinyl)-3-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-09-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-phenyl-5-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-10-5 CAPLUS
 CN Carbonic acid, (2Z)-3-[2,2'-bithiophen]-5-yl-2-fluoro-2-propenyl (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 545417-13-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-11-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-12-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 545417-14-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 2-A

PAGE 1-A



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A



RN 545417-15-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(5-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A



RN 545417-16-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(2-pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A



RN 545417-18-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(3-pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A




RN 545417-19-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(4-pyridinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 545417-20-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-(4-pyrazinylphenyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 545417-22-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 545417-23-0 CAPLUS


PAGE 2-A



RN 545417-21-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(3-pyridazinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A



RN 545417-24-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(1H-1,2,4-triazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A





PAGE 2-A



RN 545417-24-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(4H-1,2,4-triazol-4-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A



RN 545417-25-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A



RN 545417-27-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(1H-imidazol-1-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 1-A



RN 545417-28-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



RN 545417-29-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-30-9 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[(1-phenyl-1H-pyrazol-4-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 545417-31-0 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[(2-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 545417-32-1 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[(3-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 545417-33-2P 545417-34-3P 545417-35-4P
545417-36-5P 545417-37-6P 545417-38-7P
545417-39-8P 545417-40-1P 545417-42-3P
545417-44-5P 545417-46-7P 545417-48-9P
545417-50-3P 545417-52-5P 545417-54-7P
545417-57-0P 545417-59-2P 545417-61-6P
545417-63-8P 545417-64-9P 545417-66-1P
545417-68-3P 545417-70-7P 545417-71-8P
545417-72-9P 545417-73-0P 545417-74-1P
545417-75-2P 545417-77-4P 545417-78-5P
545417-79-6P 545417-80-9P 545417-81-0P
545417-82-1P 545417-83-2P 545417-84-3P
545417-85-4P 545417-86-5P 545417-87-6P
545417-88-7P 545417-89-8P 545417-90-1P
545417-91-2P 545418-52-8P 545418-53-9P
545420-57-3P 545420-58-4P 545427-97-3P
545427-98-4P 545427-99-5P 545431-22-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 545417-33-2 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[(4-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 545417-34-3 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[(5-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545417-35-4 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-(6-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

RN 545417-36-5 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-(7-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 545417-37-6 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-(8-quinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545417-38-7 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-(2-quinoxaliny)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 545417-39-8 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-(6-quinoxaliny)-2-propenyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)


Absolute stereochemistry.
Double bond geometry as shown.



RN 545417-40-1 CAPLUS

CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-(4-isoquinolinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 545417-42-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(2-oxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 545417-44-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(5-oxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 PAGE 1-A




PAGE 2-A



RN 545417-46-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(2-thiazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 PAGE 1-A




PAGE 2-A



RN 545417-48-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(2-thienyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 PAGE 1-A




PAGE 2-A



RN 545417-50-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(3-isoxazolyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

RN 545417-52-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(1,3,4-oxadiazol-2-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

RN 545417-54-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(1,2,4-oxadiazol-3-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

RN 545417-57-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(1,2,4-oxadiazol-5-yl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A

RN 545417-59-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[1-methyl-1H-benzimidazol-2-yl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-61-6 CAPLUS
 CN Carbonic acid, (2Z)-3-[4-(5-bromo-2-pyrimidinyl)phenyl]-3-fluoro-2-propenyl (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A



RN 545417-64-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-[4-(5-ethyl-2-pyrimidinyl)phenyl]-3-fluoro-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A



RN 545417-63-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(5-fluoro-2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A




RN 545417-66-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(4-methyl-2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A





PAGE 2-A



RN 545417-68-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(4-methoxy-2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



RN 545417-72-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[5-(4-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-73-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[5-(2-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 2-A





RN 545417-70-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[5-(2-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545417-71-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[5-(3-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-74-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[5-(4-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-75-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[5-(5-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-77-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(3-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-78-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(2-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-81-0 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(2-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-82-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(4-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-79-6 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(3-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-80-9 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(4-pyridinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-83-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(5-pyrimidinyl)-2-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-84-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[5-(2-pyridinyl)-3-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-85-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[5-(3-pyridinyl)-3-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 545417-86-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-(2-phenyl-5-pyrimidinyl)-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 545417-89-8 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 4-[4-(2-pyrimidinyl)phenyl]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-87-6 CAPLUS
 CN Carbonic acid, (2Z)-3-[2,2'-bithiophen]-5-yl-3-fluoro-2-propenyl (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-88-7 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(2-pyrimidinyl)oxy]phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 545417-90-1 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545417-91-2 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545418-52-8 CAPLUS
 CN Carbamic acid, [[(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 545418-53-9 CAPLUS
 CN Carbamic acid, [[3-(3-quinolinyl)-2-propynyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 545420-57-3 CAPLUS
 CN Hydrazinecarboxylic acid, 2-methyl-2-[2-(4-pyrazinylphenyl)ethyl]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 545420-58-4 CAPLUS
 CN Hydrazinecarboxylic acid, 2-methyl-2-[2-(4-pyridazinylphenyl)ethyl]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 546127-97-3 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl 5-[4-(2-pyrimidinyl)phenyl]pentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 546127-98-4 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(6-methylpyridazinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

PAGE 1-A




PAGE 2-A




RN 546127-99-5 CAPLUS
 CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-3-fluoro-3-[4-(6-methoxypyridazinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 546131-22-0 CAPLUS
CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-(4-pyrazinylphenyl)-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A



PAGE 2-A




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



IT 545420-80-2P 545423-33-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acyl ketolide deriva. of erythromycin useful as antibacterials)
RN 545420-80-2 CAPLUS
CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2Z)-2-fluoro-3-[5-(3-pyridinyl)-3-thienyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 545423-33-4 CAPLUS
CN Carbonic acid, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl (2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

ACCESSION NUMBER: 2003:42284 CAPLUS
DOCUMENT NUMBER: 138:90019
FILE: Preparation of C12 modified erythromycin macrolides and ketolides having antibacterial activity
INVENTOR(S): Chu, Daniel; Burger, Matthew; Lin, Xiaodong; Carroll, Georgia Law; Plattner, Jacob; Rico, Alice
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 252 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004509	A2	20030116	WO 2002-US21209	20020703
WO 2003004509	A3	20030515		
W: AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003125266	A1	20030703	US 2002-190431	20020703
EP 1404693	A2	20040407	EP 2002-746862	20020703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.: US 2001-302825P P 20010703 WO 2002-US21209 W 20020703				
OTHER SOURCE(S): HARPAT 138:90019				
GI				




AB Antimicrobial macrolide I wherein: V is OCORx, carbonyl, caldinoso moiety; Rx is H, alkyl, 1 O-alkyl, NH-alkyl, N-(alkyl)2; Y and Z taken together define a group X, wherein X is O, N-OH, substituted oxime; Y and Z are

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
independently H, OH, protected hydroxy, amine; T is ether, amine, alkyl, R is H, alkyl, alkenyl, alkynyl, R1 is H, alkyl, alkenyl, alkynyl, aryl, CHO, COOH, CN, ester, amide, acyl, thioester; R2 is H, halogen, alkyl; R3 is H, hydroxy protecting group; R4 is alkyl, halogen, OH, alkoxy, alkenyl, alkynyl; R5 is OH, amino, alkylamino; R1R5 are together epoxide, carbonyl, olefin; as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compns. comprising such compds.; methods of treating bacterial infections by the administration of such compds.; and processes for the prep. of the compds. Thus,
(3aS,4R,7R,9R,10R,11S,13R,15R,15aR)-3a,4-diethyl-11-methoxy-7,9,11,13,15-pentamethyl-2,6,8,14-tetraoxo-1-[4-quinolin-4-yl-butyl]tetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl-3,4,6-trideoxy-3-(dimethylamino)-D-5-xilo-hexopyranoside was prepd. and tested in vitro as antibacterial agent. The pharmaceutical compns. of this invention can be administered to humans and other animals orally, rectally, parenterally, topically (as by powders, ointments, or drops), or as an oral or nasal spray, or a liq. aerosol or dry powder formulation for inhalation.

IT 484670-98-6P 484670-98-6P 484671-02-5P
484671-14-9P 484671-20-7P 484671-24-1P
484671-38-7P 484671-40-1P 484671-63-8P
484671-83-2P 484673-79-2P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of c modified erythromycin macrolides and ketolides having antibacterial activity)


RN 484670-98-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-D-5-xilo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 484670-98-6 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-quinolinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-D-5-xilo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 484671-20-7 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-methyl-3-pyridinyl)-1H-imidazol-1-yl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-D-5-xilo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 1-B

RN 484671-24-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-methyl-4-[4-(3-pyridinyl)-1H-imidazol-1-yl]pentyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-D-5-xilo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
Absolute stereochemistry.




RN 484671-02-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(2-quinolinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-D-5-xilo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 484671-14-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-diethyl-7-fluorooctahydro-1-[4-(1H-imidazo[4,5-b]pyridin-1-yl)butyl]-11-methoxy-7,9,11,13,15-pentamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-D-5-xilo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 484671-38-7 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-diethyl-7-fluorooctahydro-1-[4-(1H-imidazo[4,5-b]pyridin-1-yl)-4-methylpentyl]-11-methoxy-7,9,11,13,15-pentamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-D-5-xilo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 484671-40-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 3a,4-diethyl-7-fluorooctahydro-1-[4-(3H-imidazo[4,5-b]pyridin-3-yl)-4-methylpentyl]-11-methoxy-7,9,11,13,15-pentamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-D-5-xilo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 484671-63-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a-ethenyl-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484671-83-2 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-3a-[(1Z)-1-propenyl]-1-[4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 484673-79-2 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[3-(4-phenyl-1H-imidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 484671-51-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-methylphenyl)-5-isoxazolyl]butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

Me

RN 484673-17-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-quinolinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 484671-49-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(3-phenyl-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484671-49-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
3a,4-diethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(3-phenyl-5-isoxazolyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-18-9 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(4-phenyl-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-19-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[4-(2-quinolinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-20-3 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-25-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[3-(4-quinolinyl)propyl]amino]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 484673-13-4P 484673-14-5P 484673-15-6P

484673-16-7P 484673-22-5P 484673-23-6P


484673-24-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of c modified erythromycin macrolides and ketolides having antibacterial activity)

RN 484673-13-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[4-(4-quinolinyl)butyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-14-5 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[4-(4-phenyl-1H-imidazol-1-yl)butyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-26-9 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[3-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]amino]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-27-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[3-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]amino]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-15-6 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[4-(2-quinolinyl)butyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-16-7 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

RN 484673-22-5 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-
pentamethyl-1-[[3-(4-(3-pyridinyl)-1H-imidazol-1-yl)propyl]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 484673-23-6 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-pentamethyl-1-[[3-(4-(3-
pyridinyl)-1H-imidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-
β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 484673-24-7 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-7,9,11,13,15-
pentamethyl-1-[[3-(4-(3-pyridinyl)-1H-imidazol-1-yl)propyl]amino]-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN

ACCESSION NUMBER: 2002:638277 CAPLUS

DOCUMENT NUMBER: 137:155147

TITLE: Preparation 6-O-carbamoyl ketolide derivatives of

erythromycin useful as antibacterials

INVENTOR(S): Henninger, Todd C.; Xu, Xiaodong

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 62 pp., Cont.-in-part of Ser.

No. US 2001-773,788.

CODEN: USXKCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002115620	A1	20020822	US 2001-11937	20011205
US 6613747	B2	20030902	US 2001-773788	20010201
US 6472372	B1	20021029		
US 2003013663	A1	20030116		

PRIORITY APPLN. INFO.: US 2000-251547P P 20001206

US 2001-773788 A2 20010201


OTHER SOURCE(S): MARPAT 137:155147

GI



AB 6-O-carbamoyl ketolide derivs. of erythromycin antibacterials of the
formula I: wherein R1 and R2 are independently H, alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, provided that R1 and R2 are not both H; R1R2
together are N atom to which they are attached, form an optionally
substituted N-containing heterocycle; R3 is H, alkylamine, alkyl, alkoxy,
alkenylamine, alkenyl, acyl, alkynylamine R4 is H, halogen, OH; R5 is a H,
hydroxy protecting group; R6 is H, alkyl, alkenyl, alkynyl, aryl,
heteroaryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl,
cycloalkenyl, alkoxyalkyl, alkylthioalkyl; X and X1 are together with the
carbon atom to which they are attached, form CO, imine, oxylimine; Y and Y1
are together with the carbon atom to which they are attached, form CO,
CHON, imine, oxylimine; were prepared. These compds. are useful as
antibacterial agents. Thus, carbamic acid [(2E)-3-[4-(2-
pyrimidinyl)phenyl]-2-propenyl]- (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-
ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-
[[3,4,6-trideoxy-3-(dimethylamino)β-D-xylo-hexopyranosyl]oxy]-2H-

L11 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

oxacyclotetradecino[4,3-d]oxazol-11-yl ester was prepd. and tested in
vitro against E. coli, S. aureus, S. epidermidis, S. pneumoniae, S.
pyogenes, Enterococci, Moraxella catarrhalis, and H. influenzae MIC values
range from 0.03 to > 16 µg/mL. These compds. are particularly useful
in the treatment of community-acquired pneumonia, upper and lower
respiratory tract infections, skin and soft tissue infections, meningitis,
hospital-acquired lung infections, and bone and joint infections.

IT 433919-44-9P 433920-41-3P 433920-43-5P

433920-45-7P 433920-46-8P 433920-48-0P

433920-49-1P 433920-50-4P 433920-51-5P

433920-52-6P 433920-57-1P 433920-72-0P

433920-73-1P 433920-74-2P 433920-75-3P

433920-76-4P 433920-77-5P 433920-78-6P


433920-79-7P 433920-81-1P 433922-58-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation carbamoyl ketolide derivs. of erythromycin useful as
antibacterials)

RN 433919-44-9 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-11-[[aminocarbonyl]oxy]-4-ethyl-7-fluorooctahydro-
3a,7,9,11,13,15-hexamethyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 433920-41-3 CAPLUS

CN Carbamic acid, [(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]-,
(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-
3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-
(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-
oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 433920-43-5 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 433920-45-7 CAPLUS
 CN Carbamic acid, [(2E)-3-(6-quinolinyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



PAGE 2-A



RN 433920-48-0 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A

RN 433920-46-8 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-A



RN 433920-49-1 CAPLUS
 CN Carbamic acid, [(2E)-3-(4-pyrazinylphenyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



RN 433920-50-4 CAPLUS
 CN Carbamic acid, [[4-(4-pyrimidinyl)phenyl]methyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433920-51-5 CAPLUS
 CN Carbamic acid, [(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Double bond geometry as shown.



RN 433920-52-6 CAPLUS
 CN Carbamic acid, [[4-(2-pyridinyl)phenyl]methyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 433920-57-1 CAPLUS
 CN Carbamic acid, [2-[[4-(2-pyrimidinyl)phenyl]methoxy]ethyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 433920-72-0 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxymino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.


PAGE 1-A



PAGE 2-A

RN 433920-73-1 CAPLUS
 CN Carbamic acid, [(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as described by E or Z.




RN 433920-74-2 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.

PAGE 1-A




PAGE 2-A




RN 433920-75-3 CAPLUS
 CN Carbamic acid, [[4-(2-pyrimidinyl)oxy]phenyl]methyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 433920-76-4 CAPLUS
 CN Carbamic acid, [(2E)-3-(3-quinolinyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.



RN 433920-77-5 CAPLUS
 CN Carbamic acid, [[4-(2-pyrimidinyl)phenyl]methyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 433920-78-6 CAPLUS

```

L11 ANSWER 10 OF 2/ CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
CN 3-oxo-2,4-dichloro-5-(2-ethyl-1-hydroxypropyl)-3a,4,7,9,10a,11b,13b,15b,
18a-18-ethyl-7-fluorotetradecino[4,3-b]pyridine-11-hydroxyimino]-3a,7,9,11,13,15-
hexamethyl-2,6,8-trioxo-10-[[4,3,4,6-trideoxy-3-(dimethylamino)-8-0-
xyllo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester
(9CI) (CA INDEX NAME)

```

Absolute stereochemistry.
Double bond geometry as described by E or Z.




CN	433920-79-7	CAPLUS
RR	Carbamic acid, [(2E)-3-(6-bromo-3-pyridinyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15AR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxylimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,6,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-9H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)	

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-
3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-
(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-2H-
oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 2-A


IT 433920-42-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation carbamoyl ketolide derivs. of erythromycin useful as
 antibacterials)

```

RN      2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
CN      11-[(aminocarbonyloxy)-4-ethyl-7-fluorooctahydro-3D,7,9,11,13,15-
        hexamethyl-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
        hexopyranosyl]oxy]-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX
        NAME)

```

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




```

RN 433920-81-1 CAPLUS
    Carbamic acid, [(2E)-3-(3-pyridinyl)-2-propenyl]-,
    (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradeca-2,6,8,10,12,14-
    (hydroxymethylino)-3,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[3,4,6-trideoxy-
    3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxyl-2H-
    oxacyclotetradecino(4,3-d)oxazol(11-yl) ester (9CI) (CA INDEX NAME)

```


Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 433922-58-8 CAPLUS
CN Carbamic acid, [(2E)-3-[4-(4-pyrimidinyl)phenyl]-2-propenyl]-,

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


Absolute stereochemistry.



IT 433919-43-8P 433920-71-9P 433920-80-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation carbamoyl ketolide derivs. of erythromycin useful as
antibacterials)

RN 433919-43-8 CAPLUS
 CN 23-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 11-[[aminocarbonyl]oxy]-4-ethyl-7-(fluorooctahydro-3a,7,9,11,13,15-
 hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-, (3aS,4R,5R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




```

RN 433920-71-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-11-[(aminocarbonyl)oxy]-4-ethyl-7-fluorooctahydro-
3a,7,9,11,13,15-hexamethyl-, 14-(O-acetylloxime),
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

```


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 433920-80-0 CAPLUS
 CN Carbamic acid, [(2E)-3-(3-pyridinyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-14-[[[acetyloxy]imino]-10-[[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as described by E or Z.



L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 infections in mammals comprising administering said compd. Thus, I [R, R3, R4, Y = H; R1 = CH2CH:CH-(3-quinolyl) (III)] was prep'd. via debenzoylation of I [R = benzoyl; R3, R4, Y = H; R1 = CH2CH:CH-(3-quinolyl)]. III was tested in vitro for its antibacterial activity (MIC = 0.01 to > 100).

IT 342036-19-5P 342036-20-8P 342036-21-9P
 342036-30-0P 342036-31-1P 342036-32-2P
 342036-33-3P 342036-34-4P 342036-35-5P
 342036-36-6P 342036-37-7P 342036-38-8P
 342036-39-9P 342036-40-2P 342036-41-3P
 342036-42-4P 342036-43-5P 342036-44-6P
 342036-45-7P 342036-46-8P 342036-47-9P
 342036-48-2P 342036-49-3P 342036-50-6P
 342036-51-7P 342036-52-8P 342036-53-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 6-O-alkyl-2-nor-2-substituted ketolide derivs. having antibacterial activity)
 RN 342036-19-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[[3-(3-quinolyl)-2-propenyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 342036-20-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[[3-(3-quinolyl)-2-propenyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:575746 CAPLUS
 DOCUMENT NUMBER: 137:125356
 TITLE: Preparation of 6-O-alkyl-2-nor-2-substituted erythromycin ketolide derivatives as antibacterial agents
 INVENTOR(S): Phan, Ly Tam; Or, Yat Sun; Ma, Zhenkun
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 43 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002103140	A1	20020801	US 2000-727934	20001130
US 6569836	B2	20030527		

PRIORITY APPLN. INFO.: US 1999-168504P P 19991202
 OTHER SOURCE(S): MARPAT 137:125356
 GI




AB Erythromycin ketolide derivs., such as I and II [R = H, hydroxy protecting group; R1 = alkyl, alkenyl, alkenyl-R2, alkynyl, alkynyl-R2; R2 = H, aryl, heteroaryl; R3 = H, OH, NH2, substituted amine, SePh, halogen; R4 = H, OH, F, Cl, Br, I, alkyl alkenyl, alkynyl, ether, ester, alkylamine; R3 and R4 taken together with the atoms to which each is attached forms a 3- to 6-membered aromatic or non-aromatic ring optionally containing a heteroatom, wherein the non-aromatic ring optionally contains one to two double bonds or R3 and R4 taken together form a =CH2, epoxide, -O-, Y = H, OH, NH2, amine; R5-R8 = H, alkyl], and pharmaceutically acceptable salts, ester, solvate or prodrug thereof, were prepared for their use as antibacterial agents. The invention relates to 6-O-alkyl-2-nor-2-substituted ketolide compound or a derivative thereof, a composition comprising the compound and a suitable carrier, a method of preparing the compound, and a method of treatment and prevention of

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-21-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluoro-7-(fluoromethyl)octahydro-3a,9,11,13,15-pentamethyl-11-[[[3-(3-quinolyl)-2-propenyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 342036-30-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-31-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-32-2 CAPLUS
 CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluorooctahydro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-35-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-36-6 CAPLUS
 CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7,7-difluorooctahydro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-33-3 CAPLUS
 CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluorooctahydro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-34-4 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-37-7 CAPLUS
 CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7,7-difluorooctahydro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-38-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(5-quinoxaliny)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-39-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-40-2 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-43-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-44-6 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-41-3 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-42-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(5-quinoxaliny)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-45-7 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-56-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-57-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-58-2 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-61-7 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(3-(3-quinolinyl)-2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-62-8 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(3-(3-quinolinyl)-2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-59-3 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-60-6 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(3-(3-quinolinyl)-2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-63-9 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(3-(3-quinolinyl)-2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 444300-05-4P 444300-06-5P 444300-07-6P
444300-13-4P 444300-14-5P 444300-15-6P
444300-16-7P 444300-17-8P 444300-18-9P
444300-19-0P 444300-20-3P 444300-27-0P
444300-28-1P 444300-29-2P 444300-30-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
(Reactant or reagent)
(prepn. of 6-O-alkyl-2-nor-2-substituted ketolide derivs. having
antibacterial activity)


RN 444300-05-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-
[[3-(3-quinolinyl)-2-propenyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 444300-06-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-
11-[[3-(3-quinolinyl)-2-propenyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-
(2-propenyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444300-15-6 CAPLUS
CN 14,1-(Nitriloethano)-2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-
trione, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-
3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444300-16-7 CAPLUS
CN 14,1-(Nitriloethano)-2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-
trione, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-
3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)


RN 444300-07-6 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7-fluoro-7-(fluoromethyl)octahydro-
3a,9,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-,
(3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 444300-13-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-
(2-propenyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444300-14-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 444300-17-8 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-
11-(2-propenyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444300-18-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-
11-(2-propenyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 444300-19-0 CAPLUS
 CN 14,1-(Nitriiloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444300-20-3 CAPLUS
 CN 14,1-(Nitriiloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 444300-29-2 CAPLUS
 CN 14,1-(Nitriiloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444300-30-5 CAPLUS
 CN 14,1-(Nitriiloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 444300-27-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444300-28-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




111 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:466704 CAPLUS
 DOCUMENT NUMBER: 137:20549
 TITLE: Preparation of tricyclic erythromycin derivatives as
 antibacterial agents
 INVENTOR(S): Wu, Yong-jin
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 12 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002077302	A1	20020620	US 2000-557528	20000424
PRIORITY APPL. INFO.:		US 1999-130913P	P 19990423	
OTHER SOURCE(S):		CASREACT 137:20549; HARPAT 137:20549		



10/075,635


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 434321-87-6 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(8-quinolinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 434321-88-7 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-hexamethyl-18-[3-(8-quinolinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 434321-89-8 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-18-[3-(7-methoxy-4-quinolinyl)propyl]-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-18-[3-(7-methoxy-4-quinolinyl)propyl]-3a,4,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434321-91-2 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(4-phenyl-1H-imidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434321-90-1 CAPLUS


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 RN 434321-92-3 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(4-phenyl-1H-imidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434321-93-4 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(4-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434321-94-5 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

Absolute stereochemistry.



RN 434321-97-8 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(2-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434321-98-9 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(2-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 hexamethyl-18-[3-(4-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434321-95-6 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(3-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434321-96-7 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(3-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

Absolute stereochemistry.



RN 434321-99-0 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(4-(3-pyridinyl)-1H-imidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434322-00-6 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-phenylpropyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 434322-01-7 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-(3-phenylpropyl)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434322-02-8 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluoro-18-[3-(3-fluorophenyl)propyl]octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 434322-03-9 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluoro-18-[3-(3-fluorophenyl)propyl]octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434322-04-0 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 18-[3-(1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)propyl]-7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 434322-05-1 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 18-[3-(1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)propyl]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434322-06-2 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(2-pyridinyl)-4-thiazolyl]propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 434322-07-3 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(2-phenyl-5-thiazolyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434322-08-4 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(2-pyridinyl)-4-thiazolyl]propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 434322-09-5 CAPLUS


CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-[2-(2-pyridinyl)-4-thiazolyl]propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434322-10-8 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 18-[3-(1H-benzimidazol-1-yl)propyl]-7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Double bond geometry unknown.

RN 434322-13-1 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[3-(4-pyridinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 434322-14-2 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[3-(4-pyridinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434322-11-9 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 18-[3-(1H-benzimidazol-1-yl)propyl]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434322-12-0 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[3-(4-pyridinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 434322-15-3 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[3-(4-pyridinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434322-16-4 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[3-(4-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 434322-17-5 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(4-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434322-19-6 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(4-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 434322-20-0 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(5-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434322-21-1 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(5-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


Absolute stereochemistry.
Double bond geometry unknown.

RN 434322-19-7 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(4-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 434322-22-2 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(5-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 434322-23-3 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(5-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
(3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 434322-24-4 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-[[3-(1H-indol-4-yl)propoxy]-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434322-25-5 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-[[3-(1H-indol-4-yl)propoxy]-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-11-[[3-(1H-indol-4-yl)-2-propenyl]oxy]-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 434322-28-8 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(8-quinolinyloxy)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434322-29-9 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(8-quinolinyloxy)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434322-26-6 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-[[3-(1H-indol-4-yl)-2-propenyl]oxy]-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 434322-27-7 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-11-[[3-(1H-indol-4-yl)-2-propenyl]oxy]-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434322-30-2 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(8-quinolinyloxy)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 434322-31-3 CAPLUS
CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(8-quinolinyloxy)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 11-[[3-(8-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 434322-32-4 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[2-[(4-quinolinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[2-[(4-quinolinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 434321-81-0P
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of tricyclic erythromycin derivs. as antibacterial agents)

RN 434321-81-0 CAPLUS
 CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 10-[(2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(4-(3-pyridinyl)-1H-imidazol-1-yl)propyl]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 434322-33-5 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[2-[(4-pyridinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434322-34-6 CAPLUS

CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(3aH,7H)-trione, 7-fluorooctahydro-3a,4,7,9,11,13,15-heptamethyl-11-[2-[(4-quinolinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15S,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434322-35-7 CAPLUS


CN 4H-1,14-(iminomethanimino)-2H-oxacyclotetradecino[4,3-d]oxazole-

L11 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

10/075,635

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCENSION NUMBER: 2002:449692 CAPLUS
 DOCUMENT NUMBER: 137:20548
 TITLE: Preparation 6-O-carbamoyl ketolide derivatives of erythromycin useful as antibacterials
 INVENTOR(S): Henninger, Todd C.; Xu, Xiaodong C.
 PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 162 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046204	A1	20020613	WO 2001-0547530	20011205
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 6472372	B1	20021029	US 2001-773788	20010201
US 2003013663	A1	20030116		
AU 2002030708	A5	20020618	AU 2002-30708	20011205
EP 1343798	A1	20030917	EP 2001-990950	20011205
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:				
		US 2000-251547P	P	20001206
		US 2001-773788	A	20010201
		WO 2001-0547530	W	20011205
OTHER SOURCE(S):	MARPAT 137:20548			
GI				




AB 6-O-carbamoyl ketolide derivs. of erythromycin antibacterials of the formula I; wherein R1 and R2 are independently H, alkyl, alkenyl, alkynyl,


L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 RN 433920-41-3 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-[(2-pyrimidinyl)phenyl]-2-propenyl]-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 2-A



RN 433920-43-5 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-[(2-pyrimidinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 86


L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 cycloalkyl, cycloalkenyl, provided that R1 and R2 are not both H; R1R2 together are N atom to which they are attached, form an optionally substituted N-contg. heterocycle; R3 is H, alkylamine, alkyl, alkoxy, alkenylamine, alkenyl, acyl, alkynylamine R4 is H, halogen, OH; R5 is a H, hydroxy protecting group; R6 is H, alkyl, alkenyl, alkynyl, acyl, heteroaryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, alkoxyalkyl, alkylthioalkyl; X and Y1 are together with the carbon atom to which they are attached, form CO, imine, oximine; Y, and Y1 are together with the carbon atom to which they are attached, form CO, CHOH, imine, oximine; were prepd. These compds. are useful as antibacterial agents. Thus, carbamic acid [(2E)-3-[4-[(2-pyrimidinyl)phenyl]-2-propenyl]- (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)β-D-xylo-hexopyranosyl)oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester was prepd. and tested in vitro against E. coli, S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes, Enterococci, Moraxella catarrhalis, and H. influenzae MIC values range from 0.03 to > 16 µg/mL. These compds. are particularly useful in the treatment of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, meningitis, hospital-acquired lung infections, and bone and joint infections.

IT 433919-44-9P 433920-41-3P 433920-43-5P
 433920-45-7P 433920-46-8P 433920-48-0P
 433920-49-1P 433920-50-4P 433920-51-5P
 433920-52-6P 433920-57-1P 433920-72-0P
 433920-73-1P 433920-74-2P 433920-75-3P
 433920-76-4P 433920-77-5P 433920-78-6P
 433920-79-7P 433920-81-1P 433922-58-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation carbamoyl ketolide derivs. of erythromycin useful as antibacterials)


RN 433919-44-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-11-[(aminocarbonyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 433920-45-7 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-[(2-pyrimidinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 433920-46-8 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(1H-pyrazol-1-yl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 433920-48-0 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 433920-49-1 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(pyrazinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 433920-50-4 CAPLUS
 CN Carbamic acid, [[4-(4-pyrimidinyl)phenyl]methyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 433920-51-5 CAPLUS
 CN Carbamic acid, [(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.




RN 433920-52-6 CAPLUS
 CN Carbamic acid, [[4-(2-pyridinyl)phenyl]methyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 433920-72-0 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxylimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 433920-57-1 CAPLUS
 CN Carbamic acid, [2-[[4-(2-pyrimidinyl)phenyl]methoxy]ethyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 433920-73-1 CAPLUS
 CN Carbamic acid, [(2E)-3-[1-(2-pyrimidinyl)-1H-imidazol-4-yl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxylimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.


L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 433920-74-2 CAPLUS
 CN Carbamic acid, [(2E)-3-[4-(3-pyridazinyl)phenyl]-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as described by E or Z.

PAGE 1-A




L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A



RN 433920-75-3 CAPLUS
 CN Carbamic acid, [[4-(2-pyrimidinyl)oxy]phenyl]methyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 433920-76-4 CAPLUS
 CN Carbamic acid, [(2E)-3-(3-quinolinyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Double bond geometry as described by E or Z.



RN 433920-77-5 CAPLUS
 CN Carbamic acid, [[4-(2-pyrimidinyl)phenyl]methyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 433920-78-6 CAPLUS
 CN Carbamic acid, [(2E)-3-phenyl-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as described by E or Z.



RN 433920-79-7 CAPLUS
 CN Carbamic acid, [(2E)-3-(6-bromo-3-pyridinyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as described by E or Z.



RN 433920-81-1 CAPLUS
CN Carbamic acid, [(2E)-3-(3-pyridinyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-14-(hydroxyimino)-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 433922-58-8 CAPLUS
CN Carbamic acid, [(2E)-3-(4-(4-pyrimidinyl)phenyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraxo-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



IT 433920-42-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation carbamoyl ketolide derivs. of erythromycin useful as antibacterials)
RN 433920-42-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[(aminocarbonyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]]-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 433919-43-8P 433920-71-9P 433920-80-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation carbamoyl ketolide derivs. of erythromycin useful as antibacterials)
RN 433919-43-8 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[(aminocarbonyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433920-71-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]]-11-[(aminocarbonyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-, 14-(O-acetyloxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 433920-80-0 CAPLUS
 CN Carbaic acid, [(2E)-3-(3-pyridinyl)-2-propenyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-14-[(acetyloxy)imino]-10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8-trioxo-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as described by E or Z.




REFERENCE COUNT: 8 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

ACCESSION NUMBER: 2002:39227 CAPLUS
 DOCUMENT NUMBER: 136:369948
 TITLE: Preparation of tricyclic erythromycin derivatives as Protozoacides and antibacterial agents
 INVENTOR(S): Wu, Yong-Jin
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 12 pp.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002061856	A1	20020523	US 2000-556642	20000424
PRIORITY APPLN. INFO.:			US 2000-556642	20000424
OTHER SOURCE(S):			MARPAT 136:369948	
GI				



AB Tricyclic erythromycins I wherein R is alkyl, alkenyl, alkynyl, wherein one or two carbons of said alkyl, alkenyl, and alkynyl groups are optionally replaced by a heteroatom; R1-R3 are independently H, alkyl, alkenyl, alkynyl, heterocycle; R2 and R3 together with the carbon to which they are attached form a 3 to 10 membered carbocyclic ring in which one or two carbons are optionally replaced by a heteroatom; R4 is H, alkyl, OH, alkoxy, aryloxy, amine, halor; R5 is alkyl, alkenyl, and alkynyl; R6 is H, ester, acyl, were prepared and used in the treatment of bacterial and Protozoa infections. Thus, I (R = Me; R1 = 3-quinolin-4-yl-propyl; R2, R3, R4, R6 = H; R5 = Me) was prepared and tested in mice for its antibacterial activity (no data).

IT 422572-03-0P 422572-05-2P 422572-07-4P
 422572-09-6P 422572-13-2P 422572-15-4P
 422572-17-6P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

(Uses)
 (prepn. of tricyclic erythromycin derivs. as Protozoacides and antibacterial agents)


RN 422572-03-0 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(8-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 422572-05-2 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(8-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 422572-07-4 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(8-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 422572-09-6 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(8-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 422572-13-2 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-hexamethyl-11-[2-[(4-pyridinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 422572-15-4 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-11-[2-[(4-quinolinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


422571-57-1P 422571-59-3P 422571-61-7P
 422571-63-9P 422571-65-1P 422571-67-3P
 422571-69-5P 422571-71-9P 422571-73-1P
 422571-75-3P 422571-77-5P 422571-79-7P
 422571-81-1P 422571-83-3P 422571-85-5P
 422571-87-7P 422571-89-9P 422571-91-3P
 422571-93-5P 422571-95-7P 422571-97-9P
 422571-99-1P 422572-01-8P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of tricyclic erythromycin derivs. as protozoacides and antibacterial agents)

RN 422571-16-2 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(4-quinolinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422571-18-4 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(5-quinolinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.




RN 422572-17-6 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,7,9,11,13,15-hexamethyl-11-[2-[(4-quinolinylmethyl)amino]ethoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 422571-16-2P 422571-18-4P 422571-20-8P
 422571-22-0P 422571-24-2P 422571-26-4P
 422571-28-6P 422571-30-0P 422571-32-2P
 422571-34-4P 422571-36-6P 422571-38-8P
 422571-40-2P 422571-42-4P 422571-44-6P
 422571-46-8P 422571-48-0P 422571-50-4P
 422571-51-5P 422571-53-7P 422571-55-9P

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 422571-20-8 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(5-quinolinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422571-22-0 CAPLUS

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-
 2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-
 methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(5-quinolinyl)propyl]-10-[[3,4,6-
 trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422571-24-2 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-
 2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-
 3a,4,7,9,11,13,15-heptamethyl-18-[3-(8-quinolinyl)propyl]-10-[[3,4,6-
 trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 422571-28-6 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-
 2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-
 18-[3-(7-methoxy-4-quinolinyl)propyl]-3a,4,7,9,11,13,15-heptamethyl-10-
 [[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 422571-30-0 CAPLUS

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




RN 422571-26-4 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-
 2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-
 methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(8-quinolinyl)propyl]-10-[[3,4,6-
 trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-
 2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-
 methoxy-18-[3-(7-methoxy-4-quinolinyl)propyl]-3a,7,9,11,13,15-hexamethyl-
 10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422571-32-2 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-
 2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-
 3a,4,7,9,11,13,15-heptamethyl-18-[3-(4-phenyl-1H-imidazol-1-yl)propyl]-10-
 [[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 422571-34-4 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(4-phenyl-1H-imidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 422571-36-6 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(4-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422571-38-8 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 422571-44-6 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(2-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422571-46-8 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(2-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(4-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422571-40-2 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(3-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422571-42-4 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(3-pyridinyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 422571-48-0 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(4-(3-pyridinyl)-1H-imidazol-1-yl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422571-50-4 CAPLUS
 CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-phenylpropyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 422571-51-5 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-{4-(3-pyridinyl)-1H-imidazol-1-yl}propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422571-53-7 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-phenylpropyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 422571-59-3 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-[3-(3H-imidazo[4,5-b]pyridin-3-yl)propyl]-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422571-61-7 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-(2-phenyl-5-thiazolyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Absolute stereochemistry.

RN 422571-55-9 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-18-[3-(3-fluorophenyl)propyl]-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422571-57-1 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-18-[3-(3-fluorophenyl)propyl]-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 422571-63-9 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-18-[3-(3H-imidazo[4,5-b]pyridin-3-yl)propyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422571-65-1 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-(2-phenyl-5-thiazolyl)propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 422571-67-3 CAPLUS

CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-18-[3-{2-(4-pyridinyl)-4-thiazolyl}propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422571-69-5 CAPLUS

CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 18-[3-{1H-benzimidazol-1-yl}propyl]-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)


Absolute stereochemistry.



RN 422571-75-3 CAPLUS

CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-11-[3-{4-pyridinyl}-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 422571-77-5 CAPLUS

CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,7,9,11,13,15-hexamethyl-11-[3-{4-pyridinyl}-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
Absolute stereochemistry.

RN 422571-71-9 CAPLUS

CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-18-[3-{2-(4-pyridinyl)-4-thiazolyl}propyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 422571-73-1 CAPLUS

CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 18-[3-{1H-benzimidazol-1-yl}propyl]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 422571-79-7 CAPLUS

CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-11-[3-{4-quinolinyl}propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422571-81-1 CAPLUS

CN 1,14-(Iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,7,9,11,13,15-hexamethyl-11-[3-{4-quinolinyl}propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 422571-83-3 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(4-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 422571-85-5 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-


L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 422571-89-9 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-hexamethyl-11-[[3-(5-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 422571-91-3 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(5-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
3a,7,9,11,13,15-hexamethyl-11-[[3-(4-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 422571-87-7 CAPLUS


CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-11-[[3-(5-quinolinyl)propoxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L11 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 422571-93-5 CAPLUS

CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-hexamethyl-11-[[3-(5-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 422571-95-7 CAPLUS


CN 1,14-(iminomethanonitrilo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 11-[[3-(1H-benzimidazol-4-yl)propoxy]-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



422572-01-8 CAPLUS
 1, 14-[[[iminomethanonitrilo]-2H-oxacyclotetradecino[4,3-d]oxazole-
 2,6,8,7(TH,9)-trione, 11-[[[3-(H-benzimidazo[4,5-l]-2-propenyl)oxy]-4-ethyl-
 7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-3a,7,9,11,13,15-hexamethyl-10-
 [[3,4,6-trideoxy-3-(dimethylamino)-8-D-xyllo-hexopyranosyl]oxy]-,
 (3aS,4R,9R,10R,11R,13R,15R,15aR)- (BCI (CA INDEX NAME))

Absolute stereochemistry.
Double bond geometry unknown.




IT 422572-11-OP
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (reduction agent; preparation of tricyclic erythromycin derivs. as
 Protozoacides

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:314957 CAPLUS

DOCUMENT NUMBER: 136:310123
 TITLE: Preparation of antibacterial 6-O-substituted erythromycin derivatives having improved gastrointestinal tolerance
 INVENTOR(S): Ma, Zhenkun; Pham, Ly Tam; Clark, Richard F.; Zhang, Souming; Djuric, Stevan
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXX2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032919	A2	20020425	WO 2001-US32278	20011016
WO 2002032919	A3	20020919		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HT, HU, ID, IL, IN, TS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, LU, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TR, TT, TZ, UA, UG, UZ, VN, VU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GA, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002013267	A2	20000429	AU 2002-13267	20011016
EP 138534	A2	20030723	EP 2001-981637	20011016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR				
PRIORITY APPL. INFO.:				
			WO 2000-240777P	P 20001016
			US 2001-US32278	P 20011016
OTHER SOURCE(S): CASREACT 136:310123; MARPAT 136:310123				
GI				



Page 98

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 aryl, heteroaryl; R1 is H, hydroxyl protecting group, were prepd. for treating bacterial infections while avoiding the concomitant liability of gastrointestinal intolerance. Thus, I wherein D1 is C.tpbond.C, Y1 is isoxazol-3,5-diyl, A1 is pyrid-2-yl, X is fluoride, R1 is hydrogen was prepd. and demonstrated an unexpected gastrointestinal tolerance. The total daily dose of the compds. administered to a patient in single or divided doses can be in amts. from about 0.1 to about 200 mg/kg body wt. or preferably from about 0.25 to about 100 mg/kg body wt. This enhanced gastrointestinal tolerability represents a significant advantage for the compds. of this invention. These compds. will have an improved side effect profile when compared with the erythromycin derivs. of the prior art. Patients consuming these compds. will experience a reduced incidence of nausea, vomiting, gastrointestinal discomfort, cramping, and other GI side effects typically assocd. with erythromycin therapy. The compds. showed antibacterial activity in vitro with MIC's in a range of about 0.004 µg/mL to about 128-µg/mL in a more preferred range, the compds. inhibited the growth of bacteria with MIC's in a range of about 0.004 µg/mL to about 2 µg/mL and in a most preferred range, the compds. inhibited the growth of bacteria with MIC's in a range of about 0.004 µg/mL to about 4 µg/mL. I.

IT 412046-93-6P 412047-22-4P 412047-24-6P
 412047-26-8P 412047-28-0P 412047-30-4P
 412047-34-8P 412047-42-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of antibacterial 6-O-substituted erythromycin derivs. having improved gastrointestinal tolerance)

RN 412046-93-6 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 412047-22-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[[3-[3-(3-chloroimidazo[2,1-b]thiazol-2-yl)-5-isoxazolyl]-2-

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 propynyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 412047-24-6 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(5-thiazolyl)-5-isoxazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 412047-26-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(2-thiazolyl)-5-isoxazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 412047-28-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[[3-[3-(3,4-difluorophenyl)-5-isoxazolyl]-2-propynyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 412047-30-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(5-pyrimidinyl)-5-isoxazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 412047-34-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(2-methyl-2H-tetrazol-5-yl)-5-isoxazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 412047-42-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[3-(quinolinyl)-5-isoxazolyl]-2-propynyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 412046-92-5 412047-23-5 412047-25-7
 412047-27-9 412047-29-1 412047-31-5
 412047-35-9 412047-43-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of antibacterial 6-O-substituted erythromycin derivs. having
 improved gastrointestinal tolerance)
 RN 412046-92-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-
 (2-propynyl)oxy-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 412047-23-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-11-[[3-[3-(3-chloromethylidene[2,1-b]thiazol-2-yl)-5-
 isoxazolyl]-2-propynyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-
 hexamethyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 412047-29-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-11-[[3-[3-(3,4-difluorophenyl)-5-isoxazolyl]-2-
 propynyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-,
 (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 412047-25-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-
 [[3-[3-(5-thiazolyl)-5-isoxazolyl]-2-propynyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 412047-27-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-
 [[3-[3-(2-thiazolyl)-5-isoxazolyl]-2-propynyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-A




RN 412047-31-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-
 [[3-[3-(5-pyridindyl)-5-isoxazolyl]-2-propynyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 412047-35-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-
 [[3-[3-(2-methyl-2H-tetrazol-5-yl)-5-isoxazolyl]-2-propynyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 412047-43-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-
 [[3-[3-(3-quinolinyl)-5-isoxazolyl]-2-propynyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 412046-91-4P
 RI: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (preparation of antibacterial 6-O-substituted erythromycin derivs. having
 improved gastrointestinal tolerance)
 RN 412046-91-4 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-
 [[3-[3-(2-pyridinyl)-5-isoxazolyl]-2-propynyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:314956 CAPLUS
 DOCUMENT NUMBER: 136:340937
 TITLE: Preparation of erythromycin ketolides as antibacterial agents
 INVENTOR(S): Hlaasta, Dennis; Henninger, Todd C.; Grant, Eugene B.;
 Khosla, Chaitin; Chu, Daniel T. W.; Ashley, Gary
 PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 108 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032918	A2	20020425	WO 2001-US32119	20011012
WO 2002032918	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6590083	B1	20030708	US 2000-691540	20001018
AU 2002013214	A5	20020429	AU 2002-13214	20011012
EP 1345953	A2	20030924	EP 2001-981580	20011012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:				
US 2000-691540 A 20001018				
US 1999-129729P P 19990416				
US 1999-131383P P 19990428				
US 1999-140175P P 19990618				
US 1999-172154P P 19991217				
US 1999-172159P P 19991217				
US 2000-548568 A2 20000413				
US 2000-548584 A2 20000413				
US 2000-550045 A2 20000414				
US 2000-551162 A2 20000414				
WO 2001-US32119 W 20011012				

OTHER SOURCE(S): MARPAT 136:340937
 GI




AB The present invention includes erythromycin ketolides I wherein: X is hydrogen or halide; R is hydrogen or a substituted or unsubstituted moiety wherein the moiety is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl; R1 is hydrogen or a substituted or unsubstituted moiety wherein the moiety is selected from the group consisting of methyl, alkyl, alkenyl, alkynyl, aryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl; R2 is hydrogen, acyl, or a hydroxy protecting group; R3 is hydrogen, hydroxyl, or -ORa wherein Ra is a substituted or unsubstituted moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl; and the pharmaceutically acceptable salts, esters and pro-drug forms thereof. These compds. possess anti-infective activity and are useful for the treatment of bacterial and protozoal infections. Thus, I (X = F, R = 1H-imidazo[4,5-b]pyridin-1-ylbutyl, R1 = Pr, R2 = F, R3 = OMe) was prepared and tested in vitro as antibacterial agent against *S. pneumoniae* (MIC ≤ 0.015).

IT 300841-16-1P 301320-09-2P 413592-00-4P
 413592-04-8P 413592-07-1P 413592-12-8P
 413592-15-1P 413592-17-3P 413592-22-0P
 RI: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of erythromycin ketolides as antibacterial agents)
 RN 300841-16-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-1-[4-(1H-imidazo[4,5-b]pyridin-1-yl)butyl]-11-methoxy-
 3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-
 β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) -
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 301320-09-2 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 413592-00-4 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(6-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 413592-12-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(7-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 413592-15-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 7-fluoro-11-[[3-(6-fluoro-3-quinolinyl)-2-propenyl]oxy]octahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 413592-04-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 7-fluorooctahydro-11-[[3-(6-methoxy-3-quinolinyl)-2-propenyl]oxy]-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 413592-07-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(6-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 413592-17-3 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 11-[[3-(6-chloro-3-quinolinyl)-2-propenyl]oxy]-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 413592-22-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-pyridinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



IT	301320-11-6	RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of erythromycin ketolides as antibacterial agents)
RN	301320-11-6	CAPLUS
CN	2H-oxacyclo[1,2:4,3]-dioxazole-2,6,8,14,18,20H)-tetrone, 10-[[2-(2-oxobenzoyl-3,4,6-trideoxy-3-(dimethylamino)-D-xylono- furanosyl)oxyl]-7-fluorooctahydro-3,7,9,11,13,15-hexamethyl-11-(2- propenyl)oxy]-4-propenyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)	


Absolute stereochemistry.



L
 ANSWER 17 OF 27 CARLUS COPYRIGHT 2004 ACS ON STM
 ACCESSION NUMBER: 2001:416950 CARLUS
 DOCUMENT NUMBER: 135:19871
 TITLE: Preparation of macrolide erythromycin
 6-O-alkyl-2-nor-2-substituted ketolide derivatives as
 antibacterial agents
 INVENTOR(S): Phan, Ly Tam; Oo, Yat Sun; Ma, Zhenkun
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001/040241	A2	20010607	WO 2000-US32767	20001201
WO 2001/040241	A3	20011213		
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1233971	A2	20020828	EP 2000-982357	20001201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2003527347	T2	20030916	JP 2001-540996	20001201
PRIORITY APPLN. INFO.:			US 1999-453261 A	19991202
			WO 2000-US32767	W 20001201
OTHER SOURCE(S):	MARPAT	135:19871		
GI				

OTHER SOURCE(S): MARPAT 135:19871
GI



AB Macrolide erythromycins I R is hydrogen or a hydroxy protecting group; R1 is selected from the group consisting of optionally substituted alkyl, alkenyl; alkenyl-Q; alkynyl; and alkynyl-Q; Q is selected from the group consisting of: hydrogen; aryl; substituted aryl; heteroaryl; substituted heteroaryl; R2 is H, OH, NH2, substituted amine, SePh, halogen; R3 is selected from the group consisting of: hydrogen; OH; F, Cl, Br or I; alkyl


L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
alkenyl, alkenyl, ether, ester, alkylamine: R2 and R3 taken together with
the atoms to which each is attached forms a 3- to 6-membered aro. or
non-arom. ring optionally contg. a heteroatom, wherein the non-arom. ring
optionally contains one to two double bonds or R2 and R3 taken together
form a =CH2, epoxide, or -O- Y is H, OH, NH2, amine were prepd. as
antibacterial agents. The present invention relates to
6-O-alkyl-2-nor-2-substituted ketolide compd. or a deriv. thereof, a
compn. comprising the compd. and a suitable carrier, a method of prep.
the compd., and a method of treatment or prevention of an mammals
comprising administering said compd. Thus (R¹ = R², R³ =
CH2C.tlpbond.C-3-quinolyl) R2R3 = CH2 Y = H) was prepd. and tested in
vitro for its antibacterial activity (MIC = 0.01 to > 128).

IT 342036-19-5P 342036-20-8P 342036-21-9P
342036-30-0P 342036-31-1P 342036-32-2P
342036-33-3P 342036-34-4P 342036-35-5P
342036-36-6P 342036-37-7P 342036-38-8P
342036-39-9P 342036-40-2P 342036-41-3P
342036-42-4P 342036-43-5P 342036-44-6P
342036-45-7P 342036-46-0P 342036-57-1P
342036-58-2P 342036-59-3P 342036-60-6P
342036-61-7P 342036-62-8P 342036-63-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of macrolide erythromycin 6-O-alkyl-2-nor-2-substituted ketolide derivs. as antibacterial agents)

RN	242036-19	5	CAPLUS	as antifolate/antimetabolite agents,
CN	2H-Oxacyclo[tetrade]cino-[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,6,11,13,15-pentamethyl-11-[[3-(3-quinolinyl)- 2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylono- hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME).			


Absolute stereochemistry.
Double bond geometry unknown.



RN 342036-20-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(3-
 quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-
 xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA
 INDEX NAME)


L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry unknown.



RN 342036-21-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluoro-7-(fluoromethyl)octahydro-3a,9,11,13,15-pentamethyl-11-
 -[3-(3-quinolinyl)-2-propenyl]oxyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-
 β-D-xylo-hexapyranosyl]oxyl]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




```

RN      342036-30-0  CAPLUS
CN      2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
        4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propenyloxy)-10-
        [3,4,6-trideoxy-3-(dimethylamino)-8-O-xylo-hexopyranosyl]oxy]-
        (3aS,4R,9R,10R,11R,13R,15R,15aR)- 9(1) (CA INDEX NAME)

```


Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-31-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-32-2 CAPLUS
CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-35-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-36-6 CAPLUS
CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-33-3 CAPLUS
CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-34-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-37-7 CAPLUS
CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7,7-difluorooctahydro-3a,9,11,13,15-pentamethyl-11-(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-38-8 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,9,11,13,15-pentamethyl-11-[[3-(5-quinoxaliny)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-39-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,4,10,11,12,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-40-2 CAPLUS
CN 14,1-(Nitridoethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-43-5 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,4,10,11,12,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-44-6 CAPLUS
CN 14,1-(Nitridoethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-41-3 CAPLUS
CN 14,1-(Nitridoethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-42-4 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7,7-difluorooctahydro-3a,4,10,11,12,13,15-pentamethyl-11-[[3-(5-quinoxaliny)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-45-7 CAPLUS
CN 14,1-(Nitridoethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7,7-difluoro-3a,4,10,11,12,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-56-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,4,10,11,12,13,15-pentamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-57-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-58-2 CAPLUS
CN 14,1-(Nitridoethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-61-7 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(3-(3-quinoliny)-2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-62-8 CAPLUS
CN 14,1-(Nitridoethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(3-(3-quinoliny)-2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-59-3 CAPLUS
CN 14,1-(Nitridoethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 342036-60-6 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(3-(3-quinoliny)-2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 342036-63-9 CAPLUS
CN 14,1-(Nitridoethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,9,11,13,15-pentamethyl-7-(3-(3-quinoliny)-2-propenyl)-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:756722 CAPLUS
 DOCUMENT NUMBER: 133:296621
 TITLE: Preparation of erythromycin macrolides as potential
 anti-infective agents
 INVENTOR(S): Chu, Daniel T. W.; Ashley, Gary W.
 PATENT ASSIGNEE(S): Kosan Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000063224	A2	20001026	WO 2000-US9914	20000414
WO 2000063224	A3	20010118		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2000042379	A5	20001102	AU 2000-42379	20000414
EP 1171446	A2	20020116	EP 2000-922149	20000414
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000010680	A	20020219	BR 2000-10680	20000414
US 6395710	B1	20020528	US 2000-550045	20000414
JP 2003523938	T2	20030812	JP 2000-612314	20000414
NZ 515027	A	20040130	NZ 2000-515027	20000414
US 2002055472	A1	20020509	US 2000-750470	20001227
US 6514944	B2	20030204		
ZA 2001009444	A	20030218	ZA 2001-9444	20011115
US 2002119938	A1	20020829	US 2002-75466	20020213
US 6593302	B2	20030715		
US 2002156028	A1	20021024	US 2002-124988	20020417
US 20030207821	A1	20031106	US 2003-357792	20030203
PRIORITY APPLN. INFO.:			US 1999-129729P	P 19990416
			US 1999-140175P	P 19990618
			US 1999-172154P	P 19991217
			US 1999-172159P	P 19991217
			US 1999-173804P	P 19991230
			US 1999-173805P	P 19991230
			US 2000-550045	A 20000414
			US 2000-551162	A1 20000414
			WO 2000-US9914	W 20000414
			WO 2000-750470	A1 20001227

OTHER SOURCE(S): MARPAT 133:296621
 GI

L11 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB Title compds. I, wherein R1 is H; substituted or unsubstituted alkyl (1-10C); substituted or unsubstituted alkenyl (2-10C); substituted or unsubstituted alkynyl (2-10C); substituted or unsubstituted aryl (4-14C); substituted or unsubstituted arylalkyl (5-20C); or OR1 is replaced by H; R2 is H or halogen; R3 is H or a protecting group; R4 is Me, unsubstituted alkyl (3-10C); substituted alkyl (1-10C); substituted or unsubstituted alkynyl (2-10C); substituted or unsubstituted aryl (4-14C); substituted or unsubstituted arylalkyl (5-20C); substituted or unsubstituted arylalkenyl (5-20C); substituted or unsubstituted arylalkynyl (5-20C); substituted or unsubstituted amidoarylalkyl (5-20C); substituted or unsubstituted amidoarylalkenyl (5-20C); or substituted or unsubstituted amidoarylalkynyl (5-20C); R5 is H or a protecting group; L is methylene or carbonyl; T is -O-, -N(R)-, -N(OR)-, -N(NHCR)-, or -N(NHCR)- wherein R is H or R1 as defined above, with the proviso that when L is methylene, T is -O-; one of 2 and Y is H and the other is OH, protected OH, or amino, mono- or dialkylamino, protected amino, or an amino heterocycle or 2 and Y together are -O-, -NOH or a derivatized oxime; including any pharmaceutically acceptable salts thereof and any stereoisomeric forms and mixts. of stereoisomeric forms thereof, are potential antimicrobial agents. Thus, 6-O-methyl-14-norerythromycin A was prepared as potential antibacterial agent.

IT 301320-11-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of erythromycin macrolides as potential anti-infective agents)

RN 301320-11-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyl)oxy]-4-propyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 301320-09-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of erythromycin macrolides as potential anti-infective agents)

RN 301320-09-2 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.





L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:756529 CAPLUS
 DOCUMENT NUMBER: 133:296619
 TITLE: Preparation of ketolide erythromycins as antibacterial agents
 INVENTOR(S): Hlasta, Dennis; Henninger, Todd; Grant, Eugene; Khosla, Chaitin; Chu, Daniel
 PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA; Kosan Biosciences, Inc.
 SOURCE: PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062783	A2	20001026	WO 2000-US10276	20000413
WO 2000062783	A3	20010215		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1171447	A2	20020116	EP 2000-923425	20000413
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002542197	T2	20021210	JP 2000-611919	20000413
ZA 2001009444	A	20030218	ZA 2001-9444	20011115
US 2002156028	A1	20021024	US 2002-124988	20020417
PRIORITY APPLN. INFO.:			US 1999-129729P	P 19990416
			US 1999-131383P	P 19990428
			US 1999-140175P	P 19990618
			US 1999-172154P	P 19991217
			US 1999-172159P	P 19991217
			US 1999-131383	A 19990428
			US 1999-173804P	P 19991230
			US 1999-173805P	P 19991230
			WO 2000-US10276	W 20000413
			US 2000-551162	A1 20000414

OTHER SOURCE(S): MARPAT 133:296619
 GI

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Ketolide antibacterials I wherein, X is H, halogen; R is selected from H, aryl, heterocyclo, cycloalkyl, alkyl, alkenyl; R1 is selected from H, alkyl, alkenyl, alkynyl; R2 is selected from H, COCH₃ and Bz; R3 is selected from H and alkoxy; were prepared as antibacterial agents. These compds. are erythromycin analogs useful in the treatment of bacterial and protozoal infections and in the treatment of other conditions involving gastric motility. Thus, I (R = R₄, R1 = Me, R2 = X = H, R3 = OMe) was prepared and tested for its in vitro antibacterial activity (MIC range is from 0.03 to > 16 µg/ml).

IT 300841-16-1P 300841-32-1P 300841-33-2P
300841-35-4P 300841-37-6P 300841-39-8P
300841-40-1P 300841-42-3P 300841-44-5P
300841-46-7P 300841-47-8P 300841-49-0P
300841-50-3P 300841-51-4P 300841-52-5P
300841-53-6P 300841-55-8P 300841-56-9P
300841-58-1P 300841-59-2P 300841-61-6P
300841-62-7P 300841-64-9P 300841-65-0P
300841-67-2P 300841-69-4P 300841-71-8P
300841-72-9P 300841-74-1P 300841-76-3P
300841-78-5P 300841-79-6P 301320-09-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ketolide erythromycins as antibacterial agents)

RN 300841-16-1 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,


L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 300841-35-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-phenyl-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300841-37-6 CAPLUS


CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-phenyl-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

7-fluorooctahydro-1-[4-(1H-imidazo[4,5-b]pyridin-1-yl)butyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300841-32-1 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-quinolinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 300841-33-2 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-quinolinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 300841-39-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300841-40-1 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 300841-42-3 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-11-hydroxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-
 pyridinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 300841-44-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-
 pyridinyl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 300841-46-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-11-hydroxy-1-[4-(3H-imidazo[4,5-b]pyridin-3-yl)butyl]-
 3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-
 D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 300841-50-3 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-heptamethyl-1-[4-(4-
 (3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-
 D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 300841-51-4 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-11-hydroxy-3a,4,7,9,11,13,15-hexamethyl-4-propyl-1-[4-(4-
 (3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-
 D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 300841-47-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-1-[4-(3H-imidazo[4,5-b]pyridin-3-yl)butyl]-11-methoxy-
 3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-
 D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 300841-49-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-11-hydroxy-1-[4-(1H-imidazo[4,5-b]pyridin-3-yl)butyl]-
 3a,4,7,9,11,13,15-heptamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-
 D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 300841-52-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-11-methoxy-3a,4,7,9,11,13,15-hexamethyl-4-propyl-1-[4-(4-
 (3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-
 D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 300841-53-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 7-fluorooctahydro-1-[4-(1H-imidazo[4,5-c]pyridin-1-yl)butyl]-11-methoxy-
 3a,4,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-
 D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300841-55-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-1-[4-(3H-imidazo[4,5-c]pyridin-3-yl)butyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300841-56-9 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[4-(7H-purin-9-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300841-58-1 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[4-(7H-purin-7-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 300841-59-2 CAPLUS


CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-1-[(2E)-4-(1H-imidazo[4,5-b]pyridin-1-yl)-2-butenyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-4-propyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



PAGE 1-A




PAGE 1-B

RN 300841-61-6 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[(2E)-4-[4-(5-pyrimidinyl)-1H-imidazol-1-yl]-2-butenyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



PAGE 1-A




PAGE 1-B

RN 300841-62-7 CAPLUS

Page 110

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[(2E)-4-[4-(5-pyrimidinyl)-1H-imidazol-1-yl]-2-butenyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300841-64-9 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[(2E)-4-[4-(5-pyrimidinyl)-1H-imidazol-1-yl]-2-butenyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 300841-65-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-4-propyl-1-[(2E)-4-[4-(5-pyrimidinyl)-1H-imidazol-1-yl]-2-butenyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 300841-67-2 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-phenyl-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 300841-69-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-phenyl-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 300841-71-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 300841-72-9 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 300841-74-1 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-hydroxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-(5-pyrimidinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 300841-76-3 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-(4-(5-pyrimidinyl)-1H-imidazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 300841-78-5 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-11-hydroxy-1-[4-(3H-imidazo[4,5-b]pyridin-3-yl)butyl]-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 300841-79-6 CAPLUS


CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethenyl-7-fluorooctahydro-1-[4-(3H-imidazo[4,5-b]pyridin-3-yl)butyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301320-09-2 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-4-propyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 301320-11-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ketolide erythromycins as antibacterial agents)
RN 301320-11-6 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyl)-4-propyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


ACCESSION NUMBER: 2000:680385 CAPLUS
DOCUMENT NUMBER: 133:238249
TITLE: Preparation of 2-halo-6-O-substituted erythromycin ketolides as antibacterial agents
INVENTOR(S): Phan, Ly Tam; Or, Yat Sun; Chu, Daniel T.; Platter, Jacob J.; Chen, Yan; Clark, Richard F.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 27 pp.
CODEN: USKXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6124269	A	20000926	US 1998-154294	19980916
PRIORITY APPL. INFO.:			US 1997-63700P	P 19971029
OTHER SOURCE(S):		MARPAT 133:238249		




AB 2-Halo-6-O-substituted ketolide derivs. I [R = H, hydroxy protecting group; R1 = alkyl, aryl, heteroaryl, substituted amine, CH2CH:CHY, CH2C.tplbond.CY; Y = H, aryl, heteroaryl, vinyl, substituted vinyl; X = H, Y = O; XY = CH2CH2] and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula STR1 compris. comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for their preparation Thus, I (R = X = H, R1 = CH2CH:CH2, Y = O) was prepared and tested for its antibacterial activity (MIC = 0.003 to > 128).

IT 223507-97-9P 223508-01-8P 223508-03-0P
223508-04-1P 223508-06-3P 223508-09-6P
223508-10-9P 223508-11-0P 223508-12-1P
223508-13-2P 223508-14-3P 223508-16-5P
223508-17-6P 223508-18-7P 223508-19-8P
223508-20-1P 223508-21-2P 223508-22-3P
223508-23-4P 223508-24-5P 223508-25-6P




223508-26-7P 223508-28-9P 223508-29-0P
223508-30-3P 223508-31-4P 223508-32-5P
223508-33-6P 223508-34-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-halo-6-O-substituted erythromycin ketolides as antibacterial agents)
RN 223507-97-9 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223508-01-8 CAPLUS
CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-chloro-4-ethyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 223508-03-0 CAPLUS
CN 14,1-(Nitriethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-bromo-4-ethyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223508-04-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(2-propenyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 223508-06-3 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 223508-11-0 CAPLUS
CN Carbamic acid, {3-[3-[[3a,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-6-quinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 223508-12-1 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[[3-(6-amino-3-quinolinyl)-2-propenyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Double bond geometry unknown.


RN 223508-09-6 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(6-nitro-3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


RN 223508-10-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(phenyl-2-propenyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 223508-13-2 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(6-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

RN 223508-14-3 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(1,8-naphthyridin-3-yl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-16-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(6-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-17-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 11-[[3-(6-(dimethylamino)-3-quinolinyl)-2-propenyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-20-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(6-(methylamino)-3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-21-2 CAPLUS
 CN 6-Quinolincarboxaldehyde, 3-[3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-18-7 CAPLUS
 CN 6-Quinolincarboxaldehyde, 3-[3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-19-8 CAPLUS
 CN 6-Quinolincarboxaldehyde, 3-[3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-22-3 CAPLUS
 CN 6-Quinolincarboxaldehyde, 3-[3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-, 6-oxime (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-23-4 CAPLUS
 CN 6-Quinolincarboxaldehyde, 3-[3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-, 6-hydrazone (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-24-5 CAPLUS
 CN 6-Quinolincarboxaldehyde, 3-[[3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]-, 6-[[1-methylethylidene)hydrazono] (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-25-6 CAPLUS
 CN 3-Pyridinecarboxaldehyde, 5-[[3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-29-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[4-oxo-4-(2-thienyl)-2-butenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223508-30-3 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[[4-(6-chloro-3-pyridinyl)-4-oxo-2-butenyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-26-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(2-propynyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223508-28-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(4-oxo-4-phenyl-2-butenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-31-4 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223508-32-5 CAPLUS
 CN 8-Quinolinesulfonamide, 3-[[3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-33-6 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 11-[(3-{2,2'-bithiophen-5-yl-2-propynyl}oxy)-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223508-34-7 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-{5-(2-pyridinyl)-2-thienyl}-2-propynyl}oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


Absolute stereochemistry.



RN 223508-07-4 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 293309-29-2 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyl)-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




IT 223508-27-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-halo-6-O-substituted erythromycin ketolides as antibacterial agents)

RN 223508-27-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propynyl)-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 223507-98-0P 223508-07-4P 293309-29-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-halo-6-O-substituted erythromycin ketolides as antibacterial agents)

RN 223507-98-0 CAPLUS

CN 14,1-(Nitriethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


L11 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2000:553251 CAPLUS
 DOCUMENT NUMBER: 133:120575
 TITLE: Preparation of erythromycins as antibacterial agents
 INVENTOR(S): Denis, Alexis; Fromentin, Claude; Heckmann, Bertrand
 PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.
 SOURCE: Eur. Pat. Appl., 17 pp.
 CODEN: EPXKDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1026170	A1	20000809	EP 2000-400286	20000203
EP 1026170	B1	20030115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2789392	A1	20000811	FR 1999-1292	19990204
FR 2789392	B1	20011005		
JP 2000229993	A2	20000822	JP 2000-21454	20000131
US 6313101	B1	20011106	US 2000-497651	20000203
AT 231160	E	20030215	AT 2000-400286	20000203
ES 2186615	T3	20030516	ES 2000-400286	20000203
PRIORITY APPL. INFO.: FR 1999-1292 A 19990204				
OTHER SOURCE(S): MARPAT 133:120575				
GI				



AB Macrolide erythromycins I (R = heterocycle, X = CH₂, NH; n = 1-8; Y = H, halogen; Z = H, acyl) were prepared as antibacterial agents. Thus, 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(1H-indol-3-yl)-1H-imidazol-1-yl]-butyl]-imino]]-erythromycin was prepared and tested in

L11 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 vitro for its antibacterial activity (MIC for S. aureus = 0.02-0.150 µg/cm³).

IT 285569-19-9P 285569-47-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of erythromycins as antibacterial agents)
 RN 285569-19-9 CAPLUS
 CN 2-Furancarboxamide, N-[1-[4-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorododecahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-1(4H)-yl]butyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B



RN 285569-47-3 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-1-[4-[(4-(1H-indol-3-yl)-1H-imidazol-1-yl)butyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:535153 CAPLUS
 DOCUMENT NUMBER: 133:135545
 TITLE: Preparation of ketolide antibiotics erythromycin derivatives as antibacterial and antiparasitic agents
 INVENTOR(S): Kaneko, Takushi; McMillen, William Thomas
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXKDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044761	A2	20000803	WO 1999-182051	19991228
WO 2000044761	A3	20010104		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, MD, MR, NE, NG, SN, TD, TG				
CA 2359708	AA	20000803	CA 1999-2359708	19991228
EP 1147121	A2	20011024	EP 1999-959627	19991228
EP 1147121	B1	20031217		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916969	A	20011106	BR 1999-16969	19991228
EE 200100394	A	20021015	EE 2001-394	19991228
JP 2002535414	T2	20021022	JP 2000-596017	19991228
AT 256694	E	20040115	AT 1999-959627	19991228
ZA 2001005580	A	20030217	ZA 2001-5580	20010706
BG 105730	A	20020329	BG 2001-105730	20010725
HR 2001000559	A1	20020831	HR 2001-559	20010725
NO 2001003680	A	20010919	NO 2001-3680	20010726
US 2002156027	A1	20021024	US 2002-116969	20020405
PRIORITY APPL. INFO.: US 1999-117342P P 19990127				
WO 1999-182051 W 19991228				
US 2000-491804 B1 20000126				

OTHER SOURCE(S): MARPAT 133:135545
 GI

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Macrolide erythromycins I (R = H, acyl, Bn, benzylloxycarbonyl, alkylsilyl; R1 = alkyl; R2 = heterocycle, aryl; R3 = H, alkyl; R4 = halogen, CN; X1 = O, -CR5R6-, -NR5-, R5, R6 = H, alkyl; X2 = O, substituted oxime) were prepared as antibacterial and antiparasitic agents. Thus, I (R = H; R1 = Me; R2 = NH(CH2)3R7; R3 = Et, R4 = F) was prepared and tested in mice for its antibacterial and antiparasitic activities.


IT 286462-85-9P 286462-86-0P 286462-87-1P
286462-88-2P 286462-89-3P 286462-90-5P
286462-92-8P 286462-94-0P 286462-96-2P
286462-98-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ketolide antibiotics erythromycin derivs. as antibacterial and antiparasitic agents)

RN 286462-85-9 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[[3-(4-(3-pyridinyl)-1H-imidazol-1-yl)propyl]amino]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methylxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 286462-86-0 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[[3-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl]amino]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, 14-(O-methylxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 286462-87-1 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[[3-(2-phenyl-1H-imidazol-1-yl)propyl]amino]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


Absolute stereochemistry.



RN 286462-88-2 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 1-[[3-(4,5-bis(acetyloxy)-1H-imidazol-1-yl)propyl]amino]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 286462-89-3 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 1-[[3-(6-amino-9H-purin-9-yl)propyl]amino]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 286462-90-6 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 1-[[3-[5-(4-chlorophenyl)-2H-tetrazol-2-yl]propyl]amino]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 286462-92-8 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[[3-(4-(2-propenyl)-1H-imidazol-1-yl)propyl]amino]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 286462-94-0 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[[3-(5-phenyl-2H-tetrazol-2-yl)propyl]amino]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 286462-96-2 CAPLUS
CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 1-[[3-[5-(2-chlorophenyl)-2H-tetrazol-2-yl]propyl]amino]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[[3-[4-(3-pyridinyl)-1H-imidazol-1-yl]propyl]amino]-, 14-(O-methylxime), (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




L11 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 286462-98-4 CAPLUS
CN Acetamide, N-[2-[[1-[3-[[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-1(4H)-yl]amino]propyl]-1H-imidazol-4-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 286463-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BTOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of ketolide antibiotics erythromycin derivs. as antibacterial and antiprotozoal agents)
RN 286463-00-1 CAPLUS

L11 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:367056 CAPLUS
DOCUMENT NUMBER: 133:4901
TITLE: Preparation of erythromycins as antibacterial agents
INVENTOR(S): Denis, Alexis
PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.; Aventis Pharma. S.A.
SOURCE: Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1004592	A1	20000531	EP 1999-402907	19991123
EP 1004592	B1	20030716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2786188	A1	20000526	FR 1998-14782	19981124
FR 2786188	B1	20021031		
AU 9959522	A1	20000525	AU 1999-59522	19991117
ZA 9907176	A	20001120	ZA 1999-7176	19991118
US 6440941	B1	20020827	US 1999-442681	19991118
JP 2000159790	A2	20000613	JP 1999-331141	19991122
NO 9905745	A	20000525	NO 1999-5745	19991123
CN 1263101	A	20000816	CN 1999-127394	19991123
KR 2000057017	A	20000915	KR 1999-52014	19991123
AT 245160	E	20030815	AT 1999-402907	19991123
BR 9905735	A	20000808	BR 1999-5735	19991124
US 2003050254	A1	20030313	US 2002-188394	20020702
US 6664398	B2	20031216		
PRIORITY APPLN. INFO.:			FR 1998-14782	A 19981124
			US 1999-442681	A3 19991118
OTHER SOURCE(S):		MARPAT 133:4901		
GI				



AB Macrolide erythromycins I (Y=H, F; n=1-8; Z=H, substituted)

L11 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 carboxylate) were prepd. as antibacterial agents. Thus,
 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-
 ribohexopyranosyl)oxy]-6-O-methyl-3-oxo-12,11-[oxycarbonyl-[[4-(3-(3-
 pyridinyl)-1H-pyrazol-1-yl)butyl]imino]]-erythromycin was prepd. and
 tested in vitro for its antibacterial activity (MIC = 0.04-0.6 μ /CM3).
 IT 270251-28-09 270251-31-5P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (derivs. of erythromycin, their process of preparation and their
 application
 as medicaments)
 RN 270251-28-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-(3-(3-
 pyridinyl)-1H-pyrazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 270251-31-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
 4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[4-(3-(3-
 pyridinyl)-1H-pyrazol-1-yl)butyl]-10-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
 PUBLICATION NUMBER: 2000:335421 CAPLUS
 DOCUMENT NUMBER: 132:322074
 TITLE: Preparation of erythromycin derivatives as antibiotics
 INVENTOR(S): Agouridas, Constantin; Denis, Alexis; Fromentin, Claude
 PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.
 SOURCE: PCT Int. Appl., 13 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027857	A2	20000518	WO 1999-FR2718	19991109
WO 2000027857	A3	20000817		
W: AS, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2785612	A1	20000512	FR 1998-14145	19981110
US 2002013281	A1	20020131	US 1999-433146	19991103
JP 2000143689	A2	20000526	JP 1999-318015	19991109
EP 1016669	A1	20000705	EP 1999-402783	19991109
EP 1016669	B1	20030219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9915236	A	20020108	BR 1999-15236	19991109
SI 20640	C	20020228	SI 1999-20091	19991109
AT 232879	E	20030315	AT 1999-402783	19991109
ES 2189365	T3	20030701	ES 1999-402783	19991109
NZ 511609	A	20030725	NZ 1999-511609	19991109
PT 1016669	T	20030731	PT 1999-402783	19991109
AU 766138	B2	20031009	AU 2000-10526	19991109
US 2002028791	A1	20020307	US 2000-734162	20001211
US 6407257	B2	20020618		
NO 2001002272	A	20010710	NO 2001-2272	20010509
ZA 2001003801	A	20020510	ZA 2001-3801	20010510
HR 2001000335	A1	20020630	HR 2001-335	20010510
HR 20010335	B1	20030831		
PRIORITY APPLN. INFO.: FR 1998-14145 A 19981110				
US 1999-433146 A3 19991103				
WO 1999-FR2718 W 19991109				
OTHER SOURCE(S): MARPAT 132:322074				
GI				


L11 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Erythromycin derivs. I, wherein X represents a hydrogen atom or a halogen atom and Z represents a hydrogen atom or an acid radical and the additive salts with acids were prepared as antibiotics. Thus, 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-ribohexopyranosyl)oxy]-6-O-methyl-3-oxo-12,11-[oxycarbonyl-[[4-(4-(4-aminophenyl)-1H-imidazol-1-yl)butyl]imino]]-erythromycin was prepared and tested in vitro for its antibacterial activity against Streptococcus pyogenes and pneumoniae (MIC = 0.3-2.5 μ g/CM3).
 IT 267000-51-1P
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of erythromycin derivs. as antibiotics)
 RN 267000-51-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 1-[4-(4-(4-aminophenyl)-1H-imidazol-1-yl)butyl]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

NH₂

IT 267000-52-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of erythromycin derivs. as antibiotics)

RN 267000-52-2 CAPLUS

CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone,
10-((2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl)oxy)-1-[4-(4-(4-aminophenyl)-1H-imidazol-1-yl)butyl]-4-ethyl-
7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-,
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L11 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:289282 CAPLUS

DOCUMENT NUMBER: 132:279475

TITLE: Preparation of macrolide erythromycins as

antibacterial agents

INVENTOR(S): Agouridas, Constantine; Bretin, Francois; Denis,

Alexis; Fromentin, Claude

PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.

SOURCE: Fr. Demande, 28 pp.

CODEN: FRMXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2784682	A1	20000421	FR 1998-12937	19981015
FR 2784682	B1	20021206		
US 6352983	B1	20020305	US 1999-416022	19991008
JP 2000128896	A2	20000509	JP 1999-290869	19991013
EP 1000952	A2	20000517	EP 1999-402523	19991014
EP 1000952	A3	20040102		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO


US 2002111319 A1 20020815 US 2002-75635 20020213

PRIORITY APPLN. INFO.: FR 1998-12937 A 19981015

US 1999-416022 A1 19991008

OTHER SOURCE(S): MARPAT 132:279475

GI



AB Macrolide erythromycins I (A = N, NO; R = H, hydroxyalkyl, aryloxyalkyl;
R1 and R2 = H, alkyl; Z = H, acyl) were prepared as antibacterial agents.
Thus, (3aS-(3aR*,4S*,7R*,9S*,10S*,11S*,13S*,15S*,15aS*))]-4-ethyl-7-fluoro-
3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-
[[3,4,6-trideoxy-3-(dimethyl-amino)-β-D-xylo-hexopyranosyl]oxy]-14,1-
(nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(9H)-trione was
prepared and tested in vitro for its antibacterial activity (MIC = 0.02-1.2
μg/cm³).

IT 263904-89-8P 263904-92-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

Page 121

PAGE 1-B

NH₂

L11 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of macrolide erythromycins as antibacterial agents)

RN 263904-89-8 CAPLUS

CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-
trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-
3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-
xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 263904-92-3 CAPLUS

CN 14,1-(Nitriloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-
trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-
(hydroxymethyl)-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-
3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR,18R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 263904-91-2P 263904-95-6P 263904-99-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of macrolide erythromycins as antibacterial agents)


L11 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 263904-91-2 CAPLUS
 CN 14,1-(Nitriothano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-(trimethylsilyl)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 263904-95-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-1-[(1R)-1-(hydroxymethyl)-2-[(phenylmethyl)amino]ethyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 263904-99-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-1-[(1R)-1-(hydroxymethyl)-2-[(phenylmethyl)amino]ethyl]-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

L11 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 ACCESSION NUMBER: 1999:659085 CAPLUS
 DOCUMENT NUMBER: 131:257819
 TITLE: Preparation of 2-fluoro-3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-6-O-methyl-3-oxo-erythromycin derivatives
 INVENTOR(S): Bonnet, Alain; Gambier, Francoise
 PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.; Aventis Pharma SA
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXKDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 949268	A1	19991013	EP 1999-400843	19990407
EP 949268	B1	20031210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2777282	A1	19991015	FR 1998-4366	19980408
FR 2777282	B1	20010420		
US 6121432	A	20000919	US 1999-273846	19990322
JP 11310591	A2	19991109	JP 1999-88580	19990330
CN 1235162	A	19991117	CN 1999-104963	19990407
CN 1130370	B	20031210		
AT 256139	E	20031215	AT 1999-400843	19990407

PRIORITY APPLN. INFO.: FR 1998-4366 A 19980408
 OTHER SOURCE(S): MARPAT 131:257819
 GI




AB Macrolide erythromycins I (A = OH; B = H; AB = carbonate, carbamate; Z = H, acyl, alkyl) were prepared. Thus, 11,12-dideoxy-3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-2a-fluoro-6-O-methyl-3-oxo-12,11-bis[oxycarbonyl[4-[(3-pyridinyl)-1H-imidazol-1-yl]]-

L11 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 Absolute stereochemistry.




RN 263905-00-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 1-[(1R)-2-amino-1-(hydroxymethyl)ethyl]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 IT 244307-90-29
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 2-fluoro-3-de[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-6-O-methyl-3-oxo-erythromycin derivs.)
 RN 244307-90-2 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-1-[[4-[(3-pyridinyl)-1H-imidazol-1-yl]butyl]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1999:299484 CAPLUS
 DOCUMENT NUMBER: 130:312023
 TITLE: Preparation of 2-halo-6-O-substituted ketolide erythromycins as antibacterial agents
 INVENTOR(S): Phan, Ly Tam; Or, Yat Sun; Chu, Daniel T.; Plattner, Jacob J.; Chen, Yan; Clark, Richard F.
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921871	A1	19990506	WO 1998-US22989	19981029
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
ZA 9809845	A	19990429	ZA 1998-9845	19981028
CA 2307788	AA	19990506	CA 1998-2307788	19981029
AU 9912881	A1	19990517	AU 1999-12881	19981029
AU 751448	B2	20002015		
EP 1027362	A1	20000816	EP 1998-956338	19981029
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO			
BR 9813319	A	20000822	BR 1998-13319	19981029
JP 2001521039	T2	20011106	JP 2000-517980	19981029
NZ 503822	A	20021220	NZ 1998-503822	19981029
NO 2000002190	A	20000629	NO 2000-2190	20000427
BG 104434	A	20010131	BG 2000-104434	20000515
PRIORITY APPLN. INFO.:			US 1997-959881	A 19971029
			US 1998-154239	A 19980916
			WO 1998-US22989	W 19981029
OTHER SOURCE(S):		MARPAT 130:312023		
GI				

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB Macrolide erythromycins I (R is hydrogen or a hydroxy protecting group; R1 = alkyl optionally substituted with one or more substituents, X is F, Cl, Br, I; CH2CH:CHY, wherein Y is selected from the group consisting of H, aryl, heteroaryl, -CH:CH2, CH:CH-aryl, CH:CH-heteroaryl, and aryl) were prepared as antibacterial agents. Thus, I (R = H, R1 = CH2CH:CH2, X = F) was prepared and tested for its antibacterial activity (MICs = 0.2-100 µg/mL).

IT 223507-97-9P 223508-01-8P 223508-03-6P
 223508-04-1P 223508-06-3P 223508-09-6P
 223508-10-9P 223508-11-0P 223508-12-1P
 223508-13-2P 223508-14-3P 223508-16-5P
 223508-17-6P 223508-18-7P 223508-19-8P
 223508-20-1P 223508-21-2P 223508-22-6P
 223508-23-4P 223508-24-5P 223508-25-6P
 223508-26-7P 223508-28-9P 223508-29-0P
 223508-30-3P 223508-31-4P 223508-32-5P
 223508-33-6P 223508-34-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-halo-6-O-substituted ketolide erythromycins as antibacterial agents)
 RN 223507-97-9 CAPLUS
 CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 4-ethyl-7-fluoro-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-01-8 CAPLUS
 CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-chloro-4-ethyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223508-03-0 CAPLUS
 CN 14,1-(Nitrioloethano)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8(7H,9H)-trione, 7-bromo-4-ethyl-3a,4,10,11,12,13,15,15a-octahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-04-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyloxy)-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223508-06-3 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(3-quinolinyl)-2-propenyloxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-09-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(6-nitro-3-quinolinyl)-2-propenyl)oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-10-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-phenyl-2-propenyl)oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-13-2 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(6-quinolinyl)-2-propenyl)oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-14-3 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(1,8-naphthridin-3-yl)-2-propenyl)oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-11-0 CAPLUS
 CN Carbamic acid, [3-{3-[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl)oxy]-1-propenyl]-6-quinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-12-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[(3-(6-amino-3-quinolinyl)-2-propenyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-16-5 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(6-quinolinyl)-2-propenyl)oxy]-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-17-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[(3-(6-(dimethylamino)-3-quinolinyl)-2-propenyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[(3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-18-7 CAPLUS
 CN 6-Quinolinesulfonamide, 3-[[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-19-8 CAPLUS
 CN 6-Quinolinesulfonamide, 3-[[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-22-3 CAPLUS
 CN 6-Quinolinesulfonamide, 3-[[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-23-4 CAPLUS
 CN 6-Quinolinesulfonamide, 3-[[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-20-1 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-[[6-(methylamino)-3-quinoliny]-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-21-2 CAPLUS
 CN 6-Quinolinesulfonamide, 3-[[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-24-5 CAPLUS
 CN 6-Quinolinesulfonamide, 3-[[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 223508-25-6 CAPLUS
 CN 3-Pyridinecarboxitrile, 5-[[3-[[[(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-4-ethyl-7-fluorotetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-26-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(2-propynyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223508-28-9 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(4-oxo-4-phenyl-2-butynyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-29-0 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(4-oxo-4-(2-thienyl)-2-butynyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223508-30-3 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[[4-(6-chloro-3-pyridinyl)-4-oxo-2-butynyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 223508-31-4 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-(3-quinolinyl)-2-propynyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223508-32-5 CAPLUS
 CN 8-Quinolinesulfonamide, 3-[3-[[3aS,4R,7S,9R,10R,11R,13R,15R,15aR]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl]oxy]-1-propynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 223508-33-6 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 11-[(3-(2,2'-bithiophen)-5-yl-2-propynyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223508-34-7 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-[(3-[5-(2-pyridinyl)-2-thienyl]-2-propynyl)oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 223507-98-0P 223508-05-2P 223508-07-4P
223508-27-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of 2-halo-6-O-substituted ketolide erythromycins as
antibacterial agents)
RN 223507-98-0 CAPLUS
CN 14.1-(Nitrilotriethalo)-2H-oxacyclotetradecino[4,3-d]oxazole-2,6,8 (7H,9H)-
trione, 10-[[[2-(2-benzoyl-1,3,4,6-tetrideoxy-3-(dimethylamino)-p-D-xylo-
hexanopyranosyl)oxy]-1,3,5,6-tetrafluoro-3a,4,10,11,12,13,15,15a-octahydro-11-
oxo-3a,7,9,10,11,13,15,15a-hexamethyl-, (3aS,4R,9R,10R,11R,13R,15R,15aR)-
(9CI), (CA INDEX NAME)

Absolute stereochemistry.



RN	223508-05-2	CAPLUS
CN	2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14 (1H,7H,9H)-tetrone, 10-[[[2-(O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo- hexopyranosyl)oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13-hexamethyl-11-(2-propenyl)oxy]-, (3Sa,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX	


L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

Absolute stereochemistry.



CN	223508-07-4 CAPLUS
RN	2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[2-O-benzoyl-3,4,6,6-trideoxy-3-(dimethylamino)-β-D-xylo- hexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11- [[3-[3-quinolino(1-2-propenyl)oxy]-, (3aS,4R,7S,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 223508-27-8 CAPLUS
 CN 2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone, 10-[[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-4-ethyl-7-fluorooctahydro-3a,7,9,11,13,15-hexamethyl-11-(2-propenyloxy)-, (3aS,4R,9R,10R,11R,13R,15R,15aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.